Literature Review: Cultured Meat: The Path to Economic Viability

This literature review synthesizes research from 2004 to 2025 to assess the economic viability of cultured meat, identifying key conditions for commercial scale. The analysis, structured around production costs, technical priorities, regulation, and market readiness, finds that growth media costs, especially serum replacement, are the primary cost bottleneck and near-term reduction opportunity. While bioprocess advancements in scaffolds and bioreactors are progressing, simultaneous maturation across all technical domains is essential. Historical cost reductions in pharmaceutical biomanufacturing offer a precedent for significant cost compression, though these trajectories unfolded over decades under different conditions. Regulatory pathways vary globally, with divergent frameworks reflecting not just governance but active political contestation from incumbent livestock industries, creating independent market barriers. Consumer acceptance is uneven, with perceptions of unnaturalness posing a persistent challenge. Ultimately, economic viability is co-determined by this political and institutional environment, revealing barriers that pure cost analysis misses. The conclusion is that achieving commercial viability requires coordinated investment, clearer regulations, interdisciplinary collaboration, knowledge transfer from adjacent sectors, and sustained engagement with the political economy of agri-food transformation.

1. Introduction

The global food system stands at a crossroads, driven by multiple converging pressures. Rising demand for animal-derived protein, intensifying pressure on agricultural land and water resources [1], growing public concern over industrial livestock’s contribution to greenhouse gas emissions [2, 3], and persistent questions about animal welfare [4] have collectively transformed alternative protein technologies from peripheral curiosities into subjects of serious scientific, economic, and policy inquiry. Among these technologies, cultured meat — the production of animal muscle tissue through the in vitro cultivation of animal cells, bypassing the need to raise and slaughter livestock — has attracted extraordinary attention from researchers, investors, and regulators alike [5, 6]. Once confined to speculative discourse, the field has matured considerably since the landmark public demonstration of a cell-cultured beef burger in 2013 [7, 8], and the literature surrounding it has expanded rapidly. Despite this momentum, cultured meat has not achieved commercial scale. The substantial gap between laboratory proof-of-concept and economically viable, widely available products [9, 10] requires advances spanning cell biology, bioprocess engineering, food regulation, market strategy, and environmental science simultaneously. A systematic review of the current state of knowledge is therefore both timely and necessary.

The period from 2018 to 2025 represents a particularly consequential chapter in cultured meat research. This timeframe encompasses several critical developments: the first regulatory approvals of cultivated meat products for human consumption, issued by Singapore’s Food Safety Authority and subsequently by United States authorities, marking a historic threshold in governance [11, 12]; more rigorous techno-economic analyses that have tempered early optimism with sober assessments of cost structures [9]; the refinement of scaffold and bioreactor technologies capable of producing structured tissue rather than undifferentiated cell slurries [13, 14, 15]; and a growing body of consumer research revealing the complexity of public attitudes toward novel protein sources [16, 17, 18]. The literature of this period is therefore uniquely rich, contested in places, and formative for understanding where the field is headed. A review grounded in this window of scholarship can illuminate not only what has been achieved but where the most consequential uncertainties and knowledge gaps remain.

Crucially, the economic challenge facing cultured meat is not without precedent in adjacent industries. The pharmaceutical biomanufacturing sector — which shares fundamental bioprocess architecture with cultured meat, including mammalian cell culture, bioreactor engineering, sterile media formulation, and capital-intensive facility infrastructure — has accumulated decades of cost reduction experience. The cost of producing a gram of monoclonal antibody has fallen from thousands of dollars in the early 1990s to figures approaching single digits, driven by process intensification, continuous manufacturing, and systematic learning-by-doing [19, 20]. Understanding whether and how these cost reduction mechanisms transfer to food-grade cellular agriculture provides an empirical framework for evaluating the economic projections that currently anchor cultured meat commercialisation discourse.

Equally important is the recognition that production cost reduction — while necessary — does not operate in an institutional vacuum. Sociotechnical transitions scholarship, particularly the multi-level perspective (MLP) developed across the sustainability transitions literature [21, 22, 23], provides a complementary analytical framework for understanding why promising technologies frequently stall despite technical readiness. The MLP situates innovations like cultured meat as niche developments contesting entrenched sociotechnical regimes — in this case, the deeply institutionalised global livestock system — whose persistence is sustained not merely by economic efficiency but by interlocking regulatory frameworks, subsidy structures, supply chain architectures, consumer habits, and political coalitions that collectively generate powerful path dependency [24]. Political economy scholarship has further demonstrated that incumbent industries do not passively await displacement but actively deploy lobbying, narrative framing, and regulatory capture to slow or redirect transitions [25, 26]. Integrating these structural perspectives into an assessment of cultured meat’s economic viability is essential for distinguishing between what is technically achievable and what is institutionally possible.

This review addresses four interconnected research questions. First, it asks what the core production costs in cultured meat are, and which cost components carry the greatest potential for reduction as the technology matures. Second, it examines what technical advances in scaffolding, growth media formulation, and bioreactor design are most consequential in driving progress toward commercial viability. Third, it maps how the regulatory landscape governing cultured meat varies across jurisdictions and what demonstrating safety and achieving market approval substantively requires [11]. Fourth, it investigates how market positioning choices and consumer acceptance dynamics shape the commercialisation strategies available to producers [16, 27, 28].

To address these questions, the review synthesises peer-reviewed studies published between 2004 and 2025, drawn from disciplines including cell biology, food science, bioprocess engineering, regulatory science, environmental life cycle assessment, consumer behaviour research, pharmaceutical biomanufacturing economics, sociotechnical transitions theory, and the political economy of agri-food system transformation. The review does not address plant-based meat analogues, fermentation-derived proteins, or insect protein except where comparison with cultured meat is directly relevant to the arguments being made. Nor does it extend to broader questions of global food security policy beyond what bears directly on cultured meat’s potential contribution and constraints.

The thematic structure of the review reflects the interdisciplinary character of the field. The first theme examines the cell biology foundations of cultured meat production, including cell source selection [29], the development of growth media — particularly the challenge of replacing foetal bovine serum with animal-free alternatives [30] — and strategies for cellular expansion. The second theme addresses the engineering systems required to scale production, encompassing scaffold design [13, 14], bioreactor configurations [15], and the bioprocess integration challenges that arise when biological and mechanical systems must function together at commercially meaningful volumes. The third theme maps the food safety and regulatory environment, comparing the governance frameworks operating across the United States, the European Union, Singapore, and other jurisdictions [11], and examining what safety demonstration and novel food authorisation substantively entail. The fourth theme brings together the economic and societal dimensions of commercialisation, analysing production cost trajectories, techno-economic modelling, and the consumer perceptions and cultural factors that will determine whether regulatory approval translates into market uptake [16, 17, 31]. The fifth and final theme subjects cultured meat to critical environmental and nutritional scrutiny, drawing on life cycle assessment literature [2, 1] and comparative nutritional analyses to evaluate whether the technology’s sustainability credentials justify its trajectory.

Taken together, these themes constitute the terrain that any credible path to economic viability for cultured meat must traverse. The review aims to provide researchers, practitioners, and policymakers with a structured account of where that terrain currently stands.

2. Methodology

The literature underpinning this review was identified and assembled through a structured search of the OpenAlex database, combining targeted keyword queries with a subsequent citation network expansion phase. Five discrete search strings were developed to capture the principal conceptual domains of the review: production cost and economic viability analysis; bioreactor design and culture media optimisation; regulatory approval frameworks; scaffolding and tissue engineering approaches to commercialisation; and consumer acceptance alongside market positioning within the broader alternative proteins landscape. Together, these queries returned 199 candidate records, from which 30 papers were retained after applying a relevance scoring threshold of 0.6 — a filter designed to exclude tangentially related material while preserving genuine thematic coverage.

Citation Network Expansion

Following the initial keyword phase, a citation network expansion was conducted to identify influential works that keyword searching alone might have missed. Forward and backward citations were examined at the first stage of this process — a standard snowballing technique known to surface seminal and methodologically adjacent works not captured by database queries alone — yielding 8 additional relevant papers against 105 rejections, and contributing a coverage delta of 0.07. Expansion was terminated once the collection reached its predefined target — a candidate pool of 90 papers sufficient to support a final corpus of 30 — rather than proceeding to further iterative stages.

Supplementary Biomanufacturing Literature

To evaluate the plausibility of cultured meat’s projected cost reduction trajectories against established industrial precedent, a supplementary search was conducted targeting the pharmaceutical and industrial biomanufacturing literature. This search identified studies published between 2006 and 2025 that engaged substantively with cost modelling, techno-economic analysis, experience curve dynamics, or quantitative process performance in biologics manufacturing, continuous bioprocessing, and recombinant protein scale-up. Key sources include comparative economic analyses of fed-batch and perfusion culture processes [32], assessments of continuous manufacturing strategies for recombinant drugs [20], and integrated economic analyses of continuous versus batch pharmaceutical manufacturing [33]. Recombinant protein expression hosts and process development trajectories [34], as well as progress in fed-batch CHO cell culture platforms [35] and N-1 perfusion intensification strategies [36], provide quantitative benchmarks against which cultured meat process assumptions can be evaluated. Papers were included where they contributed meaningfully to understanding cost dynamics, economies of scale, learning curve effects, or capital and operational expenditure structures in biomanufacturing contexts directly analogous to the bioprocess challenges facing cultured meat production. This supplementary corpus provided the empirical benchmarks and analytical frameworks necessary to assess whether cost projections in the cultured meat literature are grounded in documented industrial experience or represent aspirational modelling without precedent.

Supplementary Sociotechnical Transitions and Political Economy Literature

To situate cultured meat’s economic viability within the structural dynamics of agri-food system transformation, a further supplementary search targeted the sociotechnical transitions and political economy literatures. This search identified studies published between 2004 and 2025 that engaged substantively with the multi-level perspective (MLP) on sustainability transitions [37, 24], strategic niche management, innovation system analysis [38], incumbent regime destabilisation [26], or the political economy of food system change [39, 40]. The MLP in particular has been applied extensively to agriculture and food systems to illuminate how niche innovations interact with incumbent sociotechnical regimes [24]. Papers were included where they contributed meaningfully to understanding how institutional structures, power relations, and governance arrangements condition the prospects for disruptive food technologies [41, 25] — providing the theoretical and empirical frameworks necessary to assess whether cultured meat’s economic trajectory is shaped by factors that production cost analysis alone cannot capture [42].

Selection and Quality Filtering

Candidate papers underwent consistent quality criteria applied across the entire corpus. To demonstrate field recognition, older papers were required to have accumulated a minimum of five citations. Simultaneously, a recency quota stipulated that at least 35% of the final corpus must fall within a two-year window, ensuring the review reflects the rapidly evolving state of cultured meat research as of 2025. These selection parameters address the dual imperative of intellectual depth and contemporary relevance that characterizes a field transitioning quickly from laboratory proof-of-concept toward commercial scale [43, 11]. This transition is evidenced by the growth to over 150 companies now operating globally in the cultivated meat space [43]. The inclusion of recent literature was particularly crucial given that regulatory approvals, cost-reduction strategies, and scale-up bioprocessing represent areas of especially rapid development [12, 17].

Processing and Retrieval

All papers in the final corpus underwent full-text analysis, ensuring that thematic coding and evidence extraction were grounded in complete source material rather than abstracts or metadata alone. During the collection process, one paper failed retrieval entirely, and four acquisitions were unsuccessful. To maintain corpus integrity, these four papers were replaced with alternative records drawn from the existing candidate pool. These replacements consisted of papers that had already cleared the selection criteria but had not yet been assigned to the primary corpus. This approach preserved the intended thematic balance without compromising the rigour or consistency of the inclusion criteria already applied.

Thematic Organisation

The final corpus — spanning publication years from 2004 to 2025 — was organised into thematic clusters reflecting the principal analytical dimensions of the review: cost structures and pathways to economic viability [44, 45, 43]; upstream bioprocess engineering [46, 47]; regulatory environments across key jurisdictions; scaffold materials and their commercial implications [13, 48, 14]; the consumer and market dimensions of cultivated meat adoption [16, 18]; biomanufacturing scale-up economics and learning curves [45, 44]; and the sociotechnical transition dynamics and political economy of agri-food system change [24, 37, 39, 41]. This clustering provided the structural logic for the synthesis presented in subsequent sections, allowing cross-cutting observations about the interdependencies between technical, regulatory, political, and socioeconomic barriers to be drawn coherently across the literature rather than treated as isolated domains.

3. Cell Biology Foundations: Cell Sources, Media Development, and Expansion

The biological science underpinning cultured meat production rests on a set of interconnected challenges: identifying and stabilizing appropriate cell sources, formulating culture media that are both animal-free and economically viable, and developing the ancillary inputs—coating agents, growth factors, immortalization strategies—that enable sustained, scalable expansion. Early work in this space borrowed heavily from regenerative medicine and pharmaceutical cell culture, but the field has progressively articulated its own requirements, particularly around cost, regulatory acceptability, and food-grade inputs. Understanding how these sub-problems have been addressed, and where they remain unresolved, is essential to evaluating the commercial readiness of cultivated meat technology.

Cell Source Selection: A Persistent Trilemma

Early assessments of cell sources framed the choice largely around feasibility: which cell type could be most readily obtained, expanded, and differentiated into muscle tissue? The foundational landscape was mapped by [49], who systematically evaluated embryonic stem cells (ESCs), adult muscle satellite cells, and induced pluripotent stem cells (iPSCs) against criteria spanning the full production workflow from sourcing to final product. This review established the conceptual trilemma that has structured subsequent debate: ESCs offer pluripotency but raise ethical concerns and face complex regulatory landscapes; iPSCs are ethically favorable and capable of unlimited self-renewal but carry risks of epigenetic instability and somatic mutation accumulation during reprogramming [50]; and satellite cells are the most practically and regulatorily tractable option but are constrained by finite replicative lifespan — typically undergoing senescence after 50–70 population doublings in accordance with the Hayflick limit [49, 50].

By 2023, this trilemma had sharpened rather than resolved. [9] reinforced the view that satellite cells remain the most commercially viable option despite their proliferative limitations, while explicitly flagging mutation-proneness as a disqualifying concern for iPSCs in food applications. [51] offered a more nuanced position, acknowledging that all three cell types remain viable starting materials with distinct trade-off profiles, and that regulatory and consumer-acceptance considerations may prove as determinative as biological ones. Crucially, [51] signaled an emerging mechanistic understanding of differentiation pathways that opens new strategic options: the identification of LPAR1 as a receptor mediating differentiation signals, alongside the use of small-molecule ERK inhibitors, suggested that chemical induction could supplement or replace traditional serum starvation. This represents a meaningful shift from early protocols that relied on serum withdrawal as the primary differentiation trigger — a method widely regarded as incompatible with fully animal-free production [30, 52]. Stout et al. [52], for instance, demonstrated that a defined serum-free medium could sustain bovine satellite cell expansion, underscoring both the tractability and the remaining technical challenges of transitioning away from serum-based differentiation cues. Whether small-molecule approaches can fully replace serum starvation across species and cell types remains an open question that current literature has not definitively resolved.

The cultivated seafood literature has introduced a further dimension to cell source strategy. [53] demonstrated that fibroblast-like cells isolated from the fins of filefish can differentiate into both skeletal muscle-like cells and adipocytes without any genetic manipulation — a finding that challenges the assumption that canonical muscle satellite cells are the obligatory starting material for all cultured meat applications. Fin-derived fibroblasts can be obtained through non-lethal biopsy, circumventing a primary logistical bottleneck in aquatic species where satellite cell isolation protocols are poorly developed [50]. More broadly, [53] argued that developmental biology, rather than biomedical tissue engineering, offers the most productive translational framework for cultivated aquatic protein, proposing the zebrafish (Danio rerio) as a mechanistic proxy for commercially relevant species whose differentiation pathways remain poorly characterised. This rationale is further supported by the zebrafish’s well-annotated genome and the genetic tractability that makes it the dominant vertebrate model organism in developmental biology [54]. The molecular conservation of adipogenic regulation — with peroxisome proliferator-activated receptor gamma (Pparγ) functioning as the master transcription factor across fish species through heterodimerisation with Retinoid X receptor alpha (Rxrα) — validates the use of pharmacological agonists already established in mammalian systems, while species-specific downstream differences caution against uncritical protocol transfer [53].

It is worth noting that the choice of cell source is not purely a biological decision; it carries significant implications for how cultured meat navigates the sociotechnical landscape. A 2024 innovation assessment combining expert interviews with technology mapping found that genetically engineered immortalised cell lines, while technically attractive for overcoming the Hayflick limit and enabling scalable production, trigger compounding regulatory and consumer barriers — particularly under the European Union’s GMO regulatory framework. This assessment revealed that the consumer segments most plausibly targeted by cultivated meat, including environmentally motivated flexitarians, exhibit the strongest aversion to genetic modification [55]. This creates a structural tension between biological optimisation and market positioning that the cell source literature has been slow to address in integrated terms [11].

Immortalization as a Scalability Bridge

The replicative ceiling of primary satellite cells—typically exhausted within a limited number of passages due to progressive senescence, during which cells lose both proliferative and differentiation capacity over extended culture periods [51]—has prompted significant investment in immortalization strategies. A landmark study by [56] demonstrated that bovine satellite cells stably expressing constitutively active bovine TERT (telomerase reverse transcriptase) and CDK4 achieved over 120 cumulative population doublings while retaining myogenic differentiation capacity. This work established that replicative senescence can be systematically circumvented without apparent loss of lineage identity, at least within the reported observation window. The TERT/CDK4 approach has since emerged as a broadly applicable immortalization strategy [50, 51], effectively converting terminally proliferation-limited primary cells into functionally stable cell lines—an essential prerequisite for supplying the unprecedented cell volumes required at industrial scale [43].

Despite this progress, [56] identified a critical gap that remains unaddressed: long-term genetic stability data beyond 120 doublings is absent. For pharmaceutical biologics, cell banks are routinely characterized at far greater passage depths, and regulatory agencies require extensive genomic stability documentation [57, 58]. Whether immortalized bovine satellite cells accumulate oncogenic mutations, chromosomal aberrations, or altered differentiation competence at higher passage numbers remains unknown. This question represents arguably the most consequential outstanding issue for the cell source sub-field, since the commercial viability of immortalized lines depends entirely on their remaining safe and functionally consistent over industrially relevant timescales.

Serum-Free Media: From Proof-of-Concept to Systematic Formulation

Parallel to cell source work, the development of animal-free culture media has progressed from demonstrating that serum-free expansion is feasible to optimizing formulations for robustness and cost. Fetal bovine serum (FBS), the conventional supplement, presents compounding problems for cultured meat: it is ethically contentious, subject to significant batch-to-batch variability, and fundamentally incompatible with the animal-free value proposition of the product [30].

The landmark contribution in the serum-free space is the Beefy-9 medium reported by [52], which used a B8 basal medium supplemented with 800 μg/mL recombinant albumin to support bovine satellite cell expansion across seven passages with 18.2 cumulative doublings. A key mechanistic finding was that recombinant albumin functions not merely as a carrier protein but as a multifaceted antioxidant that stabilizes and transports critical compounds—a role previously fulfilled non-specifically by the complex mixture of proteins in fetal bovine serum. This mechanistic clarity helped explain why earlier serum-free formulations had often failed: they substituted individual known components while neglecting the buffering and stabilizing functions of albumin [30].

Building on this foundation, [59] extended the serum-free media development program to additional muscle cell contexts, further demonstrating that robust proliferative capacity could be maintained without serum across multiple systems. Complementary work by [60] explored food-industry by-products—including plant hydrolysates and yeast extracts—as low-cost growth-promoting agents in serum-free formulations for skeletal muscle cells, broadening the palette of candidate supplements beyond recombinant proteins. The convergence of these efforts established a working paradigm: defined media built around a B-series basal core, supplemented with recombinant albumin and targeted growth factors, can sustain satellite cell expansion for commercially meaningful numbers of passages. Recombinant production of key growth factors such as FGF2 has itself matured considerably, with engineered thermostable variants reducing the cost and frequency of supplementation [61].

An alternative approach was explored by [62], who combined Chlorella vulgaris extract (CVE) with conditioned medium from rat liver epithelial cells to support primary bovine myoblast proliferation in a formulation that is simultaneously serum-free and grain-nutrient-free. This approach is notable because grain-derived nutrients present supply chain and allergen concerns for food production contexts. The study revealed that two CVE extraction methods—acid hydrolysis and ultrasonic fractionation—yield complementary nutrient profiles, with ultrasonic fractionation uniquely preserving glutamine and asparagine. This complementarity suggests that blended or sequenced extraction strategies may be necessary to capture the full nutritional utility of microalgae-based supplements [62]. While promising as a sustainability-oriented alternative to conventional supplements, this approach introduces its own regulatory and compositional standardization challenges [12].

A notable limitation across the serum-free media literature is the absence of standardized benchmarking protocols. Formulations developed in different laboratories are evaluated under different conditions, using different cell isolates, passage numbers, and outcome metrics, making cross-study comparison unreliable [51]. This lack of standardization is not merely a methodological inconvenience; it constitutes a genuine barrier to the field’s ability to identify the most effective formulations and communicate progress credibly. Moreover, the precise formulation knowledge needed for commercially competitive media is often proprietary, limiting open scientific progress and constraining the kind of cumulative, industry-wide learning that experience curve theory predicts should accelerate cost decline [55].

Growth Factor Production and Cost Reduction

The high cost of recombinant growth factors represents a major component of media expenses, with recombinant proteins accounting for up to 95% of serum-free media costs [43]. This cost pressure has made microbial expression systems a distinct research priority for the cultured meat field. A promising approach involves exploring growth factor orthologs across species: [61] demonstrated that 21 fibroblast growth factor orthologs from both terrestrial and aquatic species could be expressed in E. coli with yields of 7–36 mg/L. Furthermore, fusion partner strategies using TrxA, DsbA, and DsbC enabled soluble expression of more challenging targets, including 21 of 25 PDGF-BB orthologs, IGF1, IGF2, and TGF-β1. This systematic characterization of orthologs serves dual strategic purposes: it simultaneously reduces per-unit production costs while addressing the field’s pronounced taxonomic bias toward bovine cells [50], thereby opening pathways toward poultry, porcine, and aquatic cell culture media development.

Industrial biotechnology literature on recombinant protein expression highlights both the promise and constraints of microbial production systems for cultured meat inputs. Among these systems, Komagataella phaffii (formerly Pichia pastoris) represents a particularly attractive host for food-grade growth factor production, having achieved FDA-granted GRAS status and featuring a tightly regulated AOX1 promoter that can drive heterologous protein accumulation to up to 30% of total cell protein [63]. Multiple recombinant protein expression platforms have been evaluated in this context, including plant-based systems that can reduce production costs by up to 98% relative to mammalian cell production [43]. However, each platform involves trade-offs in post-translational modification capacity and regulatory complexity. Comprehensive reviews of yeast expression systems identify persistent scale-up challenges — including oxygen transfer bottlenecks at high cell densities, heterogeneous mixing environments, and hypermannosylation of secreted glycoproteins — that complicate the translation from laboratory yields to industrial volumes [64].

These fermentation engineering constraints are directly relevant to the cultured meat media supply chain. The cost-effective large-scale production of recombinant albumin and growth factors — identified by [52] as essential for Beefy-9 — depends on resolving precisely the scale-up challenges that the yeast expression literature has documented but not yet fully overcome.

Sustainable Media Recycling and Food-Grade Inputs

Recent work in this research cluster has begun addressing both the downstream economics and regulatory architecture of media use. [65] reported in 2025 that an alkalization-stripping method achieves greater than 82% ammonia removal efficiency from spent media at pH 12. Importantly, a 50:50 blend of treated spent media and fresh media supports lamb satellite cell growth at rates comparable to fresh media alone. Since ammonia accumulation is a well-documented inhibitor of cell proliferation in bioreactor culture [45], its effective removal represents a prerequisite for any viable recycling strategy. This work demonstrates that spent media—a waste stream that would otherwise require disposal—can be partially recycled, substantially reducing both cost and environmental footprint. Given that culture media has been identified as one of the dominant cost drivers in cultivated meat production [44, 43], even partial recycling carries significant techno-economic implications. The methodology draws explicitly from wastewater treatment engineering, illustrating the value of cross-disciplinary transfer in solving cultured meat production challenges [66].

Also in 2025, [67] reported the development of iCoater, a food-grade gelatin-based cell culture coating agent manufactured through food-grade processes and terminally sterilized by steam autoclaving. While gelatin and extracellular matrix coatings are necessary to support cell adhesion in monolayer culture [68, 48], conventional reagents such as Matrigel are neither food-grade nor manufactured under food-safety frameworks. iCoater maintained biological performance comparable to conventional reagents and demonstrated twelve-month storage stability despite suboptimal physicochemical properties. This represents an important demonstration that the regulatory-by-design principle—where food-safety compliance is built into the production process rather than retrofitted—is technically achievable.

Together, these two studies by [65] and [67] represent a maturation of the field’s thinking. The challenge is no longer only whether biological performance targets can be met, but whether the entire input supply chain can be restructured to meet food manufacturing standards from the outset.

4. Scaffolding, Bioreactor Design, and Bioprocess Engineering

If cell biology establishes what cultured meat can be, engineering infrastructure determines what it can become at commercial scale. Resolving the biological question of how to coax stem cells into muscle and fat tissue is necessary but insufficient: without scalable, food-safe, and economically tractable engineering systems to support, structure, and harvest those cells, biological performance cannot translate into manufacturable product. This section addresses the three interlocking engineering sub-themes that the current literature has most thoroughly examined — scaffold biomaterials, bioreactor design, and lessons imported from pharmaceutical biomanufacturing — while tracing a cross-cutting tension that runs through each: the persistent gap between what has been demonstrated at benchtop scale and what remains unvalidated at pilot or industrial scale. Early reviews established the foundational parameters governing this challenge, while subsequent work has progressively refined both the material and bioreactor design spaces. The most recent literature indicates that the field is converging on a set of preferred technologies — microextrusion bioprinting, perfusion and hollow fiber bioreactors, and plant- or polysaccharide-derived scaffolds — though critical gaps between benchtop demonstration and industrial validation remain largely unresolved.

Scaffold Biomaterials: From Design Criteria to Material Selection

Early systematic analysis established a demanding set of simultaneous constraints for scaffold viability in cultivated meat. To be effective, scaffold materials must achieve greater than 90% cell attachment rates, contribute no more than 5% of total production costs, degrade within two to three weeks, and maintain porosity in the range of 30–90% with pore sizes between 50–150 μm for myogenic differentiation and 40–400 μm for adipogenic cells [13]. These specifications address biological functionality, economic feasibility, and product safety simultaneously — a tripartite constraint that no single material class satisfies without trade-offs.

Among the candidates surveyed in early literature, plant-derived decellularized scaffolds attracted considerable attention due to their naturally evolved three-dimensional architectures, mechanical compliance, and low-cost sourcing. Decellularized spinach leaves, celery stalks, apple hypanthium, and textured soy protein were all identified as structurally appropriate substrates that retain vascular channel networks potentially useful for nutrient perfusion [13]. The appeal of agricultural waste streams as scaffold feedstocks has since been further explored, with repurposed plant-based materials identified as promising low-cost candidates whose existing supply chains and food-safe status reduce both procurement costs and regulatory friction [69]. Fungal mycelium emerged as a parallel candidate, offering a filamentous architecture that mimics connective tissue organization while remaining edible and scalable through fermentation [13, 14]. By the mid-2020s, this foundational enumeration had been further contextualized against the cost and regulatory landscape, with a 2025 review noting that scaffold material selection intersects with regulatory approval pathways and downstream textural requirements [11].

The debate between plant-derived and synthetic polymer scaffolds as cost-performance solutions at industrial scale remains unresolved. Plant-derived options carry the advantages of biological familiarity, edibility, and supply chain accessibility, but their degradation kinetics and batch-to-batch variability remain poorly characterized in the context of final product texture [10]. Synthetic polymer scaffolds offer greater tunability of mechanical properties and degradation rates but raise concerns about cost, regulatory status as food-contact materials, and consumer acceptance [13, 15]. Recent bioengineering reviews have reinforced this tension, noting that while synthetic materials enable precise control of scaffold architecture and mechanical stiffness, the absence of established food-safety precedents creates a more burdensome regulatory pathway relative to food-industry-derived alternatives [48]. Systematic comparison of scaffold degradation rates and their textural consequences across these material classes constitutes a notable gap in the current literature. A 2024 innovation assessment reinforced the relative tractability of scaffolding technologies compared to other production bottlenecks, identifying hydrogels and porous scaffolds derived from established food-industry materials as offering pathways that lower both cost and cultural resistance precisely because their material basis is already familiar within food manufacturing contexts — suggesting that scaffolding need not introduce novel societal friction in the way that, for instance, genetic engineering of cell lines does [55].

Biofabrication approaches have introduced a third material design space: edible bioinks formulated specifically for three-dimensional printing of structured meat architectures. A 2024 analysis identified plant- and bacterial-derived polysaccharides — including agarose, alginate, cellulose, gellan gum, pectin, and xanthan gum — as the primary viable candidates for edible bioinks, emphasizing their animal-free status, non-allergenic profiles, and nutritional contributions as dietary fiber [70]. Complementary work on scalable edible scaffold processes has further highlighted the capacity of such polysaccharide-based systems to support structured co-culture of muscle and fat cells, which is a prerequisite for achieving the marbled textures characteristic of whole-cut meat products [14]. This framing repositions scaffold biomaterials not merely as passive substrates but as active contributors to the nutritional and textural identity of the final product.

Bioreactor Design and the Scale-Up Imperative

The case for transitioning cultivated meat production from manual, flask-based culture to automated bioreactor systems was clearly articulated in early bioprocess engineering reviews. The fundamental economic rationale centers on achieving high cell densities with minimal human labor and media waste to reach financial viability [46]. However, selecting a bioreactor configuration introduces significant trade-offs between volumetric efficiency, shear stress exposure, oxygen transfer capacity, and suitability for anchorage-dependent cells [71, 47].

One of the most striking quantitative comparisons in this literature concerns hollow fiber versus stirred tank reactor configurations. Early analysis estimated that hollow fiber bioreactors could theoretically require as little as 1.4 liters of reactor volume to produce one kilogram of cultured meat, compared to approximately 570 liters for stirred tank systems — a difference of roughly two orders of magnitude [46]. This dramatic efficiency advantage stems from the high surface-area-to-volume ratio of hollow fiber membranes and their capacity to decouple nutrient delivery from bulk fluid volume. Despite this apparent advantage, hollow fiber systems have not emerged as the consensus solution primarily because harvest and scale-up challenges — extracting cells or tissue constructs from within the fiber matrix at commercially relevant scales — have not been adequately addressed in published validation studies [46, 15].

Subsequent literature has significantly broadened the bioreactor taxonomy. A 2023 review classified bioreactor systems along two intersecting axes: medium administration mode (batch, fed-batch, continuous, and perfusion) and mixing mechanism (mechanical agitation, rotating wall vessel, hydraulic, and pneumatic systems). Each combination presents distinct profiles of shear stress, oxygen transfer efficiency, and suitability for three-dimensional tissue formation [15]. Rotating wall vessel systems, originally developed for NASA microgravity research, have attracted particular interest for their capacity to maintain low-shear suspension conditions favorable to scaffold-based 3D constructs [15, 6]. Perfusion bioreactors were identified as particularly promising for structured meat products because they enable continuous medium exchange without mechanical disruption of developing tissue constructs, maximizing both medium efficiency and spatial organization of cells [15]. Techno-economic analysis has further underscored the advantage of perfusion over fed-batch modes, with continuous medium replenishment reducing per-unit media costs at scale [44, 32]. This analysis was reinforced by broader reviews that noted the importance of matching bioreactor hydrodynamics to the mechanical sensitivity of differentiating myogenic cells [72, 47].

The most recent cost-projection work has introduced airlift reactors as a candidate for economically optimized expansion, with estimates suggesting production costs approaching approximately $17perkilogramunderidealizedairliftconfigurations[11].Airliftdesignsareattractiveinpartbecausepneumaticmixingavoidsthemechanicalimpellersresponsibleforthemostdamagingshearforcesinstirredsystems,potentiallyimprovingviabilityofsensitiveprogenitorcells[47,6].However,the$17/kg figure is derived from modeling rather than empirical validation, and real-world performance data at pilot scale remains absent from the published literature [44]. This gap — between modeled projections and demonstrated performance — characterizes the bioreactor field broadly, with most configurations validated only at benchtop proof-of-concept scale.

Lessons from Pharmaceutical Bioreactor Economics

The cultured meat bioreactor literature can be substantially informed by the more mature techno-economic evidence base in pharmaceutical biomanufacturing, where analogous trade-offs between batch, fed-batch, perfusion, and continuous configurations have been rigorously quantified. The foundational insight from this adjacent field is that process economics cannot be evaluated for individual unit operations in isolation; upstream bioreactor performance, downstream processing, and facility overhead must be treated as an interconnected economic system in which inefficiencies compound and improvements propagate across the entire cost profile [19]. This integrated modelling standard, established for monoclonal antibody manufacturing, has direct applicability to cultured meat, where the interplay between media cost, bioreactor configuration, and harvest efficiency determines the final cost-of-goods in ways that single-variable analyses cannot capture — a dynamic confirmed in cultured meat-specific modelling, where media alone comprises 41–83% of operating expenses depending on bioreactor scale and configuration [44].

Quantitative comparisons from the pharmaceutical sector offer instructive benchmarks for the cultured meat bioreactor debate. In biologics manufacturing, alternating tangential flow (ATF) perfusion consistently achieves approximately 20% cost-of-goods-per-gram savings relative to fed-batch across all evaluated scales and titers, while spin-filter perfusion becomes progressively less competitive at larger scales due to a 1.8-fold increase in material costs and inherent scale-out limitations [32]. These findings were generated using stochastic dynamic simulation models that capture scheduling complexity, equipment failure risk, and parametric uncertainty — methodological sophistication that the cultured meat techno-economic literature has not yet adopted but would benefit substantially from emulating. Existing cultured meat TEA studies, while valuable for establishing order-of-magnitude cost estimates, have predominantly relied on deterministic steady-state models that do not propagate uncertainty through the full production system [44, 45]. More broadly, economic analyses of integrated continuous pharmaceutical manufacturing have documented capital expenditure reductions of 20–76% relative to batch processing, with operating expenditure improvements that remain robust even under adverse yield assumptions [33]. The consistency of these findings across multiple independent analyses lends confidence to the general proposition that continuous and perfusion-based approaches can deliver meaningful cost advantages, though the specific magnitude is sensitive to process configuration, scale, and product-specific cost drivers — a conditionality that applies equally to cultured meat projections.

The demonstration by [73] that high-density perfusion cell culture could sustain viable cell densities of 50–60 × 10⁶ cells/mL for over 60 days, with direct integration to periodic counter-current chromatography for 30 days of uninterrupted automated operation, establishes a performance benchmark that contextualises the aspirations of cultured meat bioreactor design. While the downstream requirements differ — cultured meat does not require chromatographic purification — the upstream challenge of maintaining high cell densities under perfusion conditions over extended durations is directly analogous. The pharmaceutical precedent suggests this is achievable but demands advanced process control infrastructure, including model predictive control systems capable of managing the nonlinear dynamics inherent in biological processes over extended run times [74]. Whether the cultured meat industry can adopt such control architectures — which represent significant capital and expertise requirements — at price points compatible with food rather than pharmaceutical margins is a question the current literature has not adequately addressed. This gap is compounded by systemic production risks unique to large-scale cell factories, including energy supply disruptions, water quality variability, and cybersecurity vulnerabilities in highly automated systems [75], all of which must be incorporated into robust stochastic TEA frameworks before confident cost projections can be made.

Microcarrier Technology and Seed-Train Strategies

For anchorage-dependent cell types, which include the satellite cells and myoblasts central to cultivated meat production, suspension culture in conventional stirred tank systems is not directly applicable without adaptation. Microcarrier technology bridges this gap by providing adhesion substrates compatible with stirred suspension environments [15, 46]. Satellite cell attachment to microcarrier surfaces is mediated by integrin receptors recognising specific ligands, making surface chemistry a primary design variable: extracellular matrix protein coatings — particularly laminin and fibronectin — enhance attachment through RGD peptide sequences, while positive surface charge and moderate hydrophilicity improve protein adsorption [68]. Substrate stiffness similarly governs cell behaviour, with an optimal range of approximately 2–12 kPa identified for satellite cell proliferation [68]. The engineering of appropriate microcarriers — balancing surface chemistry for attachment, density for suspension dynamics, and material composition for edibility or removal — intersects with both the scaffold biomaterial literature and the bioreactor design literature, though integrated treatment of these two domains remains limited. Edible microcarriers fabricated from natural polymers such as cellulose, chitosan, alginate, collagen, or gelatin are increasingly regarded as the most operationally attractive option, as they eliminate the dissociation, separation, and harvesting steps that currently introduce cell losses estimated at 15–25% per passage with conventional temporary carriers [68].

Seed-train strategies, which describe the sequential expansion of cells across progressively larger reactor volumes from initial culture through to production scale, have been identified as essential for achieving the population expansions required for commercial output. Conventional planar systems are constrained to yields on the order of 10¹¹ cells, whereas commercial viability demands 10¹²–10¹³ cells; satisfying even ten percent of global meat consumption would require approximately two million cubic metres of bioreactor capacity [71]. Scaling from approximately ten thousand cells to ten trillion cells per ton of meat necessitates carefully managed passaging protocols to preserve proliferative capacity and genomic stability across successive generations [11]. The compounding risk of genetic and epigenetic instability across extended culture is a recognized concern, particularly for pluripotent stem cell lines where the selective pressures of long-term culture can lead to adaptation artifacts [11, 10].

The pharmaceutical biomanufacturing literature offers a directly relevant innovation for addressing seed-train bottlenecks: the N-1 perfusion seed strategy, in which perfusion is applied at the penultimate seed stage to generate high-density inocula that dramatically compress and intensify the subsequent production culture. [36] demonstrated across four proprietary monoclonal antibodies that high-density seeding combined with systematic media reformulation achieved normalised titer improvements exceeding 100% — a doubling of output within standard 10–14 day culture windows — with successful scale-up to 500-litre bioreactors. Critically, the study showed that high seeding density alone, without corresponding media rebalancing, compressed culture duration but did not substantially raise final titers, illustrating that process intensification is a multivariate challenge in which individual elements must be co-optimised [36]. This finding has direct implications for cultured meat seed-train design: simply increasing inoculation density without reformulating the nutritional environment will not yield the productivity gains that economic viability demands. The N-1 perfusion approach also partially addresses the genetic stability concern by reducing the total number of population doublings required between seed bank and production harvest, potentially mitigating the accumulation of culture-adapted mutations that [56] identified as an unresolved risk for immortalised cell lines.

Bioprinting, Bioassembly, and the Whole-Cut Challenge

The aspiration to produce structured whole-cut products — steak-like formats with spatially organized muscle, fat, and connective tissue — has driven interest in bioprinting and bioassembly approaches. A 2024 systematic assessment concluded that microextrusion bioprinting is the most practically viable biofabrication modality for cultivated meat, offering the best available balance among throughput, material compatibility, versatility, and scalability compared to inkjet, laser-assisted, or bioassembly-only alternatives [70]. Nevertheless, the same analysis acknowledged that resolution limitations and deposition speeds remain obstacles to producing centimeter-scale constructs with authentic whole-cut tissue architecture — a constraint corroborated by broader tissue engineering assessments noting that replicating the hierarchical fiber organization and vascularization of native muscle tissue remains an unsolved problem at commercially relevant scales [10, 66].

The gap between unstructured formats — minced or nugget-type products achievable without scaffolding — and true whole-cut structured products represents a persistent and underaddressed challenge across the literature reviewed [13, 70, 43]. While unstructured formats are closer to near-term commercial viability [10, 14], they do not capture the premium market segments that would most strongly differentiate cultivated meat from plant-based alternatives [76, 77]. The integration of bioprinting systems with bioreactor environments, enabling simultaneous fabrication and culture within a unified automated production line, is conceptually described but not yet demonstrated at meaningful scales [70, 15, 12]. This integration challenge — combining scaffold architecture, bioreactor fluid dynamics, nutrient delivery, and automated harvest into a coherent manufacturing system — constitutes perhaps the most significant outstanding engineering problem in the field as of the mid-2020s [66, 55], and it is a challenge whose resolution will require precisely the kind of cross-domain process integration that the pharmaceutical biomanufacturing precedents reviewed here begin to illuminate.

5. Food Safety, Regulatory Frameworks, and Global Governance

The governance of cultured meat as a food product sits at the intersection of novel biotechnology, public health protection, and international trade policy, making it one of the more contested and rapidly evolving areas in the broader literature on alternative proteins. From early foundational work identifying unique hazard profiles to the most recent regulatory-by-design strategies emerging in 2025, scholarship in this area has moved from problem identification toward increasingly concrete governance solutions—though substantial divergence across jurisdictions continues to complicate the path to global market access. Crucially, this divergence is not merely a product of different institutional traditions or risk assessment methodologies; it also reflects the active political contestation of incumbent agricultural interests whose strategies of lobbying, regulatory venue-shopping, and coalition-building shape the regulatory environment in which cultured meat must operate.

Hazard Identification and the Unique Food Safety Profile of Cell-Based Production

Early scholarship recognized that cultured meat does not simply reproduce conventional meat’s risk profile in a new setting; rather, it introduces an entirely distinct set of hazards rooted in cell culture biology. Foundational work by [58] established what has since become the canonical framework for thinking about these risks. Drawing on workshops with 87 industry representatives, the authors documented that mycoplasma contamination affects between 5% and 35% of cell lines globally—a striking range that reflects both the difficulty of detection and inconsistent quality assurance across facilities. Equally significant was their finding that 20–50% of commercial fetal bovine serum (FBS) contains detectable viral contaminants, positioning serum dependency not merely as an ethical or cost concern but as a direct food safety liability [30]. This dual-hazard framing—microbial contamination from biological inputs combined with genetic and chemical risks from the culture environment—provided the conceptual scaffold on which subsequent regulatory analysis has built.

By 2020, broader reviews were beginning to situate these hazards within regulatory and sustainability frameworks simultaneously [78], reflecting an emerging recognition that technical and governance challenges could not be addressed in isolation. The question of genetic instability, in particular, gained prominence: cells maintained through extended passage in culture are prone to chromosomal aberrations and epigenetic drift, raising concerns about phenotypic unpredictability and, potentially, oncogenic transformation [11]. Regulatory and governmental experts have further noted that while tumorigenicity from ingested cultured cells is considered scientifically implausible, the possibility that cultured cells could endogenously produce novel toxins or allergens warrants systematic characterization of individual cell lines [57]. The 2022 review by [79] added texture to the allergenicity dimension, noting that novel proteins introduced through culture media components, scaffold materials, or growth factors may present immunological risks not captured by existing food allergen databases—a concern amplified by the absence of any standardized testing protocol specific to cultured meat matrices. Particularly illustrative is the case of bovine insulin-like growth factor-1 (IGF-1), which shares structural identity with human IGF-1, raising unresolved questions about physiological effects at food-consumption levels [57].

The most comprehensive hazard synthesis to date appears in the 2025 scoping review by [80], which systematically aggregated evidence across eight databases to map critical control points across the full production chain. Their analysis confirms that genetic stability, microbiological integrity, chemical contamination from media residues, physical hazards from scaffold materials, and allergenicity collectively constitute the principal risk categories—each requiring distinct monitoring strategies. Crucially, this work also documents the still-limited evidence base: the majority of safety assessments remain short-term animal feeding studies, and human consumption data are effectively absent, leaving long-term toxicological profiles uncharacterized. This evidentiary gap is compounded by the near-total absence of publicly accessible industry safety data, a consequence of proprietary constraints that hinder the development of standardized testing frameworks and regulatory benchmarks [57, 81]. The gap is not merely an academic concern; it is the primary rationale cited by precautionary regulators for delaying approval, and addressing it will require coordinated, proactive data-sharing between industry, academia, and regulatory bodies [57].

Comparative Jurisdictional Analysis: A Fragmented Global Landscape

The regulatory geography of cultured meat is defined by striking divergence, and understanding this divergence requires tracing the specific institutional logics operating in each jurisdiction. The United States represents the most elaborated example of purpose-built oversight architecture: a formal agreement between the FDA and USDA divides jurisdiction such that FDA oversees cell collection, cell banks, and cell growth, while USDA assumes responsibility from the point of harvest through processing and labeling [80, 58]. This dual-agency model reflects the legacy classification of meat inspection under USDA authority and has been described as a pragmatic compromise, though critics note it creates potential gaps at the interface between the two agencies’ mandates [11]. Notably, the safety evaluation dimension of this framework draws heavily on FDA’s existing food additive and GRAS (Generally Recognized as Safe) authorities, neither of which was designed with continuous bioreactor-based production in mind [58, 81].

Singapore’s regulatory trajectory stands in sharp contrast and represents the clearest proof of concept for commercial approval. The Singapore Food Agency (SFA) granted the world’s first regulatory authorization for the commercial sale of cell-cultured chicken in 2020, operating through a risk-based pre-market assessment process that evaluated safety data submitted by the producer [80, 82]. Singapore’s approval has served as a reference point in the literature, demonstrating that regulatory pathways can be operationalized without new legislation, though the small-market context limits its generalizability [79]. Within the European Union, the situation is substantially more restrictive: cultured meat falls under the Novel Foods Regulation (EU) 2015/2283, which requires extensive pre-market dossiers and centralized authorization through EFSA evaluation—a process that has not yet resulted in any approved product and that many observers regard as structurally slow relative to the pace of technological development [80, 78]. The safety assessment obligations under this regulation are considerable, encompassing compositional analysis, toxicological data, and allergenicity evaluations, creating a lengthy dossier burden that disproportionately affects smaller firms [81].

China and Japan occupy different positions on the permissiveness spectrum. China, despite hosting active domestic research programs, has maintained restrictions on commercialization, with cultured meat categorized under novel food regulations that require state-level approval—a process that has not advanced to commercial authorization as of the most recent literature [80, 11, 9]. Japan has adopted a comparatively open stance toward research and has announced intentions to develop a dedicated regulatory framework, but formal approval mechanisms remain incomplete [82]. The net result, as [80] document, is a fragmented global landscape in which products approved in one jurisdiction face legal prohibition in others, creating substantial barriers to international trade and potentially distorting investment flows toward permissive markets. Investor analysis corroborates this dynamic, with agribusiness investors identifying regulatory uncertainty and jurisdictional inconsistency as compounding the already significant cost and scaling challenges facing the sector [83].

A recurrent debate in the comparative literature concerns whether cultured meat is better governed through adaptation of existing novel food frameworks or through purpose-built legislation. Early work favored the former on pragmatic grounds [78], but more recent analysis suggests that existing frameworks were not designed to address the full complexity of cell-based bioprocessing, particularly the continuous nature of production, the role of living biological systems as inputs, and the iterative product reformulation that characterizes the sector [80, 11]. The safety implications of these features—including potential for phenotypic drift in long-term cell lines and the use of growth factors and scaffolding materials with limited regulatory precedent—compound the inadequacy of frameworks built around conventional processed food categories [81, 58]. The tension between industry urgency for rapid approval and regulators’ precautionary posture—grounded in genuinely limited long-term safety data—runs through the literature as an unresolved structural tension rather than a problem approaching resolution.

The Political Economy of Regulatory Divergence

However, framing jurisdictional divergence solely as a product of different institutional traditions and risk assessment philosophies understates the role of organised political action in shaping regulatory outcomes. Discourse network analysis of 134 U.S. newspaper articles published between 2008 and 2023 has revealed that two distinct advocacy coalitions have crystallised around the cellular agriculture policy subsystem: a pro-cellular agriculture coalition of 62 organisations exhibiting high internal cohesion (network density of 0.74), and a pro-animal agriculture coalition of 30 organisations with lower but still significant internal coordination (density of 0.49) [25]. The fact that these coalitions have hardened into identifiable structures well before a mature regulatory framework has been established implies that the politics of cultured meat regulation are not downstream consequences of commercialisation but upstream determinants of it — shaping which agencies gain jurisdiction, what evidence thresholds are imposed, and how labelling requirements are constructed [25]. This dynamic is reinforced by the broader structure of food system transitions, in which incumbent actors with established supply chains, retailer relationships, and consumer brand recognition are well positioned to contest the terms on which novel protein categories enter regulated markets [39].

The incumbent livestock industry’s capacity to influence regulatory environments draws on institutional resources — lobbying infrastructure, congressional relationships, and trade association networks — that are well documented in the broader political economy of agriculture but are only beginning to receive specific analytical attention in the cultured meat context. Sociotechnical transitions scholarship on regime destabilisation provides instructive parallels: longitudinal analysis of the British coal industry between 1913 and 1967 demonstrated that incumbent regimes can persist through prolonged competitive and regulatory pressure by deploying accumulated political capital and maintaining cognitive commitment among industry actors, even when economic fundamentals deteriorate [26]. The multi-level perspective on sustainability transitions further identifies incumbent regime actors as capable of actively shaping landscape pressures and niche emergence through political as well as economic means, contesting both the framing of problems and the attribution of solutions [37]. Applied to the livestock sector, this framework suggests that regulatory resistance to cultured meat is not merely a conservative bureaucratic reflex but reflects the active mobilisation of regime-level institutional resources to defend an incumbent system whose actors remain cognitively committed to existing practices and expectations — a dynamic that will not dissolve simply because a superior technology becomes available [26].

It is worth noting that the pharmaceutical biomanufacturing sector has recently navigated an analogous regulatory harmonisation challenge. The adoption of ICH Q13 between 2023 and 2024 — the first globally harmonised regulatory framework specifically addressing continuous manufacturing — fundamentally altered the risk calculus for continuous bioprocessing by converting regulatory uncertainty from a speculative variable to a defined pathway [20]. This precedent suggests that regulatory harmonisation, while slow, is achievable when sufficient technical evidence accumulates and when regulators across jurisdictions engage collaboratively. The cultured meat sector currently lacks an equivalent coordinating mechanism, and the development of shared safety assessment methodologies — analogous to what ICH Q13 accomplished for manufacturing process validation — could substantially reduce the market fragmentation documented above [57]. However, the political economy analysis suggests that such harmonisation will face opposition not only from bureaucratic inertia but from organised incumbent interests with material stakes in maintaining regulatory heterogeneity and procedural complexity [25].

Regulatory-by-Design Strategies and Food-Grade Input Development

A significant development in the 2025 literature is the emergence of regulatory-by-design product development as a documented strategy [11], moving beyond compliant adaptation of existing laboratory-grade inputs toward proactive integration of regulatory requirements into the design process itself. This shift is particularly urgent given that food-safety guidelines have not been firmly established for many cultured meat inputs—including media components, scaffolding materials, and growth factors—many of which lack demonstrated food-grade standards or prior use as food additives [57]. [67] provide the most concrete illustration of this approach: their development of iCoater, a food-grade gelatin-based cell culture coating agent manufactured through food production processes and subjected to terminal steam sterilization, directly addresses the regulatory exposure created by using laboratory-grade adhesion factors. The finding that this food-grade agent achieves sterility assurance while maintaining biological performance comparable to conventional reagents—and stability over twelve months—demonstrates that the trade-off between regulatory compliance and technical function is not inevitable. This is further reinforced by parallel work on food-industry-derived serum-free media components [60], including screening of food industry by-products as growth-promoting agents, and scaffolding materials designed with edible, food-safe substrates [13], which collectively suggest that food-grade substitution is technically feasible across multiple input categories. Regulatory experts have similarly emphasized that standardization of shared basal media components—such as amino acids, vitamins, and salts—could meaningfully streamline safety evaluation across the sector [57]. Taken together, these advances represent a meaningful refinement of the hazard landscape sketched by [58], where serum and non-food-grade media components were identified as primary contamination risks, by demonstrating that substitution is not merely theoretically possible but empirically validated.

Labelling, Nomenclature, and the Politics of Market Legitimacy

Labelling and nomenclature debates, while sometimes treated as secondary to safety questions, carry significant regulatory and consumer-trust implications [79, 82]. Whether products should be labeled “cultured,” “cell-based,” “lab-grown,” or allowed to carry conventional meat nomenclature is contested across jurisdictions and directly affects consumer transparency and competitive fairness with conventional producers. Research consistently shows that the terminology applied to cultured meat products measurably shifts consumer acceptance and willingness to pay, with descriptors like “cell-based” or “cultivated” producing more favourable responses than “lab-grown” in several survey contexts [16, 18]. Notably, Bryant and Barnett’s systematic review of consumer acceptance literature finds that even the framing of “clean meat” outperforms “lab-grown meat” in acceptability, operating through associative mechanisms that link terminology to perceived naturalness and safety — underscoring that naming choices are not merely semantic but carry measurable commercial consequences [16]. The literature consistently identifies labelling as an area requiring harmonized international standards that do not yet exist [80].

Importantly, the political economy literature reframes labelling disputes not as neutral governance design questions but as proxy battles over market legitimacy with profound commercial consequences [25]. The choice of terminology — whether a product may legally be called “meat” or must carry distinguishing qualifiers — directly affects consumer perception and competitive positioning, and incumbent agricultural interests have invested significant political resources in restricting the use of conventional meat terminology for cultured products [25, 7]. Nadeau and Berardo’s discourse coalition analysis of the cellular agriculture policy subsystem documents how conventional livestock and meat processing interests have organised as a coherent advocacy bloc to contest the symbolic boundaries of food nomenclature, deploying regulatory and legislative channels to mandate distinguishing labels [25]. These naming contests reflect deeper political struggles between challenger and incumbent industries over who controls the symbolic boundaries of the food system, and regulatory decisions on terminology carry commercial weight that extends well beyond consumer information policy.

Cultivated seafood occupies a partially distinct regulatory niche, with specific sustainability and ecological considerations layered atop the standard cultured meat safety framework. [54] document that wild fish stocks face severe depletion under current pressures, framing cell-based fish production as a sustainability imperative rather than merely a novelty. The regulatory frameworks applicable to cultured seafood are, if anything, less developed than those for terrestrial meat, with marine species presenting additional complexity around sourcing of primary cells, species authentication, and the environmental claims that producers may legitimately make [54, 58, 53]. Ong et al. further note that seafood’s particular vulnerability to species substitution and mislabelling fraud introduces an additional authentication dimension absent from most terrestrial meat regulation, one that cell-based production could either exacerbate or resolve depending on how traceability frameworks are designed [58].

Gaps and Outstanding Questions

Across the literature, several gaps recur with notable consistency. The absence of long-term human consumption data remains the foundational evidentiary limitation, with no jurisdiction having accumulated the post-market surveillance data that would allow comprehensive safety characterization [80, 58]. Allergenicity testing protocols remain unharmonized and inadequately validated for cultured meat matrices — a challenge compounded by the need to assess not only known allergens but also novel proteins for potential de novo sensitization, for which no standardized detection methods yet exist [79, 57]. Mutual recognition agreements between regulatory authorities — which would substantially reduce the market fragmentation documented above — remain aspirational. And regulatory frameworks for hybrid products blending cultured and plant-based or conventional meat components are virtually absent from both the regulatory and academic literature, despite the commercial logic of such formulations [82, 11]. The 2025 literature has advanced the field considerably in mapping these gaps with precision, but the translation from hazard identification and jurisdictional description to operational, internationally harmonized governance remains the central unfinished project of this domain — a project whose completion will depend as much on the resolution of political contestation between incumbent and challenger coalitions as on the accumulation of scientific evidence. Discourse network analysis of the U.S. cellular agriculture policy subsystem confirms this polarization empirically, identifying two dominant coalitions — pro-cellular agriculture and pro-conventional animal agriculture — with an inter-coalition polarization index of −0.88, indicating that congruence ties occur overwhelmingly within rather than between coalitions [25].

6. Production Cost Economics, Consumer Acceptance, and Commercialization Strategy

The economic viability and social acceptance of cultured meat are not parallel concerns but deeply entangled ones: the price point at which a product reaches consumers shapes whether it can recruit willing buyers, while consumer willingness-to-pay in turn defines the commercial targets that production economics must meet. Understanding this intersection requires tracing a literature that has evolved from early feasibility assessments to increasingly granular cost modelling and more sophisticated consumer research, with 2025 publications sharpening the picture while also exposing persistent gaps.

Techno-Economic Realities: Cost Structures and the Growth Medium Problem

Early scholarly engagement with cultured meat economics established a foundational tension between theoretical promise and practical cost barriers. By the late 2010s, it was already clear that the biological requirements of cell culture — specifically the nutrient-rich liquid media in which cells proliferate — would dominate any cost analysis. [84] identified culture media as one of five core technical challenges for commercial-scale production, framing the problem in terms of both cost and ethical acceptability, given the field’s historic reliance on fetal bovine serum (FBS). That reliance is itself deeply problematic: FBS is derived from the blood of bovine fetuses collected during cattle slaughter, with over two million fetuses contributing to approximately 800,000 litres of global FBS supply annually, raising both ethical and food-safety concerns — including the risk of viral, mycoplasma, and prion contamination — that compound the purely economic case for its replacement [30]. This framing proved prescient: subsequent quantitative analyses confirmed that growth media is not merely a significant cost driver but an overwhelming one. [10] reported that culture media accounts for over 99% of cultivated meat production costs, a figure that renders all other production variables — scaffolding, bioreactor operation, energy — nearly negligible by comparison. This single-factor dominance means that the entire economic trajectory of the industry hinges on whether animal-free, cost-effective media formulations can be developed and scaled. Despite six decades of research into FBS alternatives, approximately 90% of published in vitro studies continue to rely on a small number of FBS-supplemented formulations, and most serum-free alternatives have thus far only replicated rather than exceeded FBS performance [30]. A 2024 innovation assessment reinforced this finding through expert interviews, documenting that the growth media bottleneck reflects not merely an ingredient cost problem but an entire upstream supply chain calibrated to pharmaceutical rather than food-production volumes and price points, generating structural cost inflation that cannot be resolved by media reformulation alone [55]. This pharmaceutical-to-food scale mismatch is stark: biopharmaceutical manufacturing typically targets products priced at $10,000–$100,000 per kilogram, whereas competitive food production demands costs closer to $9 per kilogram [44].

The cost projections that emerged from this period varied dramatically depending on assumptions about growth medium costs, creating what [76] characterised as a range stretching from rough parity with chicken to prohibitively expensive. This spread is not merely a reflection of uncertainty; it reflects fundamentally different scenarios about technological progress. Independent techno-economic assessments have further cautioned that even optimistic assumptions about media cost reductions may be insufficient without parallel advances in cell density, bioreactor productivity, and downstream processing [45]. Modelling across bioreactor scenarios confirms this interdependence: media costs comprise between 41% and 83% of operating expenses depending on reactor scale and configuration, with individual components such as transferrin, insulin, glutamine, and arginine representing the largest cost drivers within the media fraction [44]. A particularly acute infrastructure constraint concerns transferrin specifically: current global production capacity stands at only 200–300 kilograms annually, against an estimated industry requirement of over 20,000 kilograms per facility per year, suggesting that media component supply chains may need to be rebuilt from the ground up — or brought in-house — before cost targets are achievable [44]. Plant-based meat proteins, by contrast, were found to cost 3.8 to 12.7 times less than livestock protein at the raw material stage, though processing costs consume approximately 94% of final crop product costs, eroding much of that raw material advantage [76]. This comparison is instructive: it illustrates that cost competitiveness depends on which segment of the production chain one examines, and that retail price benchmarks cannot be read directly from input costs.

More recent techno-economic work has introduced greater specificity into what had been relatively coarse projections. [11] reported that airlift bioreactor designs, combined with scalable seed-train approaches to cell expansion — growing populations from roughly 10,000 to 10 trillion cells per ton of product — could potentially reduce production costs to approximately $17perkilogram.Techno-economicmodellingcorroboratesthisestimate,findingthata262,000-litreairliftreactorscenarioachievesacostofgoodssoldof$17/kg at a media cost of $1.40perlitre,fallingfurthertoapproximately$10/kg only when media costs are reduced to around $0.75 per litre — underscoring that bioreactor engineering advances are necessary but not sufficient without corresponding media cost reductions [44]. While this figure remains above the price points of industrially produced chicken in most markets, it represents a meaningful step toward the cost-parity targets that would unlock mass-market viability [43]. The same review highlighted that pluripotent stem cells, particularly induced pluripotent stem cells (iPSCs), offer the most promising cellular substrate for scalable production due to their unlimited self-renewal capacity, though concerns about genetic and epigenetic instability at scale introduce uncertainties that pure cost models do not fully capture [11, 51].

Pharmaceutical Biomanufacturing as an Economic Benchmark

The cost projections circulating in the cultured meat literature gain substantially in credibility — or lose it — when evaluated against the documented cost reduction trajectories of analogous biomanufacturing industries. The pharmaceutical biologics sector provides the most relevant empirical benchmark, sharing fundamental bioprocess architecture with cultured meat: mammalian cell culture, bioreactor engineering, sterile media formulation, and capital-intensive facility infrastructure. Mammalian cells, particularly CHO cell lines, account for approximately 84% of approved recombinant biopharmaceutical products [34], underscoring the depth of industrial experience accumulated in exactly the cell culture systems most relevant to cultured meat. The cost of producing monoclonal antibodies has fallen from thousands of dollars per gram in the early 1990s to figures now approaching single digits, a reduction achieved through the systematic interaction of learning curve effects, economies of scale, and process intensification rather than any single breakthrough [19, 20]. This trajectory demonstrates that biological manufacturing can achieve dramatic cost compression, but the timescale — approximately two decades of sustained industrial investment and process refinement — is sobering for a cultured meat industry seeking commercial viability within a much shorter horizon.

The integrated cost modelling framework established by [19] for monoclonal antibody manufacturing is particularly instructive for evaluating cultured meat projections. That foundational analysis demonstrated that upstream bioreactor productivity, downstream processing efficiency, and facility utilisation rates are the dominant cost determinants in biologics production, and that optimising any single variable without reference to the others yields misleading conclusions about manufacturing viability. Applied to the cultured meat context, this principle suggests that the $17/kg airlift bioreactor projection reported by [11] — which is derived primarily from upstream cell expansion assumptions — may understate total production costs if downstream processing, harvest inefficiency, and facility underutilisation are not simultaneously optimised. The pharmaceutical experience makes clear that decisions made early in process development disproportionately shape the long-term cost trajectory, a lesson that argues for techno-economic modelling as a standard component of cultured meat process design from the outset rather than a retrospective validation exercise.

Quantitative comparisons from biologics manufacturing further contextualise the bioreactor configuration choices facing the cultured meat sector. Continuous and perfusion-based pharmaceutical manufacturing consistently demonstrates capital expenditure reductions of 20–76% relative to batch processing, with cost-of-goods improvements on the order of 20–50% [33, 32, 20]. These figures provide empirical grounding for the general proposition that transitioning cultured meat from batch flask-based culture to continuous or perfusion bioreactor systems should yield meaningful cost reductions. However, the pharmaceutical precedent also reveals an important caveat: these gains are modality-specific and scale-dependent. ATF perfusion achieves approximately 20% cost savings relative to fed-batch that hold across scales, while spin-filter perfusion becomes less competitive at larger volumes due to escalating material costs [32]. For cultured meat, where the final product must be orders of magnitude cheaper per kilogram than therapeutic biologics, the specific magnitude of bioreactor cost advantage matters enormously, and the pharmaceutical data suggest that configuration choice will need to be optimised against food-specific cost structures rather than extrapolated directly from pharmaceutical benchmarks.

The concept of experience curves — the empirical observation that unit production costs decline by a predictable percentage with each doubling of cumulative production volume — offers a framework for estimating realistic timelines for cultured meat cost parity with conventional meat. Cross-industry analyses of technology cost reduction distinguish three principal high-level mechanisms: research and development, economies of scale, and learning-by-doing, with R&D typically dominating over learning-by-doing in manufacturing contexts where throughput remains limited [85]. In pharmaceutical biomanufacturing, learning rates have been documented across bulk fermentation, enzyme production, and monoclonal antibody manufacturing, with consistent evidence that cumulative production experience drives cost reductions through process optimisation, yield improvement, and operational learning-by-doing [20, 19]. For cultured meat, where cumulative global production volumes remain negligible, the experience curve is effectively at its starting point, meaning that R&D-driven improvement — rather than learning-by-doing — is likely to be the primary cost reduction lever in the near term [85]. Applying even optimistic learning rates to the current cost base suggests that multiple doublings of cumulative production — requiring sustained capital investment over years to decades — will be necessary before costs approach consumer market thresholds. This finding tempers the more aggressive cost reduction timelines sometimes implied in industry projections and argues for a more transparent separation between what is physically achievable and what is achievable within a commercially relevant timeframe.

A critical distinction between pharmaceutical and food biomanufacturing, however, concerns purity requirements and their cost implications. Therapeutic biologics must meet exacting specifications for purity, sterility, and lot-to-lot consistency that drive a substantial share of manufacturing cost, particularly in downstream chromatographic purification and quality assurance testing. Process development for recombinant proteins requires systematic integration of upstream cultivation, media optimisation, and downstream purification, with each stage adding cost and complexity that is directly tied to the stringency of the final product specification [34]. Cultured meat, by contrast, is a food product whose final form tolerates — and indeed requires — compositional heterogeneity. There is no need for chromatographic purification of a steak. This fundamental difference in product specification means that certain cost components that dominate pharmaceutical COG — particularly downstream processing, which can account for 50–80% of biologics manufacturing cost — are either absent or radically simplified in a food production context [19, 86]. The implication is that cultured meat’s cost reduction trajectory need not follow the pharmaceutical timeline precisely; the lower purity threshold could accelerate cost convergence if upstream productivity challenges — particularly media cost and cell density — can be resolved. Conversely, food-grade production introduces its own cost pressures that pharmaceuticals do not face, including the need for vastly greater production volumes per unit revenue, consumer price sensitivity orders of magnitude more acute than in healthcare markets, and food-safety frameworks that lack the established cost-sharing mechanisms (insurance, reimbursement) of pharmaceutical supply chains.

Commercialization Pathways and the Niche Market Strategy

Given these production economics, the commercialization literature has generally converged on a staged entry model. [87] framed commercialization as an active process already underway by 2022, shaped by regulatory and market access barriers that vary substantially across jurisdictions. Singapore’s commercial approval of cultivated chicken in late 2020 established a proof-of-concept for regulatory pathways [9, 11, 10], while the United States, European Union, and China have adopted more cautious or restrictive stances [88]. This regulatory geography matters economically because market entry in permissive jurisdictions allows firms to accumulate operational data, refine processes, and build brand familiarity before facing the stricter evidentiary requirements of larger markets.

The niche premium market strategy — positioning cultured meat as a luxury or sustainability-premium product rather than a direct commodity substitute — has been discussed as a viable bridging mechanism [78, 87], but it depends on a consumer segment willing to pay a significant price premium, whose size is contested in the empirical literature. Systematic reviews of consumer acceptance studies conducted between 2018 and 2020 document substantial cross-national variation in both willingness to try and willingness to pay, with price sensitivity emerging as one of the most consistent barriers to adoption [16, 17]. More recent evidence reinforces this: reviews of consumer perception research confirm that information provision and familiarity can modestly shift acceptance, but that cost remains the dominant structural barrier, particularly outside high-income urban demographics [18, 89]. Hybrid products combining cultured cells with plant-based matrices have been proposed as a way to reduce the proportion of expensive cell-derived material while maintaining sensory qualities — a strategy elaborated in the plant-based and cell-based production literature as potentially accelerating market entry at lower price points [76] — though systematic techno-economic analysis of this pathway remains limited [44].

However, the political economy literature complicates purely economic readings of commercialisation pathways by foregrounding the structural conditions under which market entry occurs. Technology disruption forecasts deploying S-curve theory have projected dramatic restructuring of animal agriculture — including cost parity for precision-fermented dairy proteins by the mid-2020s and a 50% reduction in U.S. cattle numbers by 2030 — theorising disruption as proceeding through ingredient substitution, end-product substitution, fortification, and form factor disruption, with business-to-business procurement identified as the primary adoption pathway [90]. The boldness of these projections has made them enormously influential in investment circles, but the forecasted timelines have proven optimistic: cost parity with conventional dairy proteins was not achieved on schedule, and industrial livestock farming shows no signs of imminent collapse. This gap between forecast and observed trajectory reflects a recurring limitation of technology disruption modelling applied to food systems: S-curve dynamics are structurally credible but temporally unpredictable, and food systems carry sociotechnical rigidities — regulatory frameworks, consumer habit formation, land tenure, labour organisation, and political coalition structures — that industrial-sector analogies do not adequately capture [24, 25, 37]. The multi-level perspective literature specifically identifies the difficulty of dislodging incumbent food regimes even under landscape-level pressure, given the co-evolutionary lock-in of infrastructure, institutions, and user practices [37, 24].

The entry of large incumbent food corporations into the alternative protein investment landscape further complicates the commercialisation picture. Empirical analysis of corporate repositioning has documented a doubling of alternative protein consumption in the United Kingdom between 2008 and 2019, alongside global investment reaching $5 billion by 2021 [39]. However, this corporate engagement represents strategic hedging rather than genuine disruption: incumbent firms are simultaneously investing in alternatives and continuing to expand conventional animal protein operations, a dynamic that the multi-level perspective on sociotechnical transitions interprets as partial regime destabilisation without structural transformation [39, 24]. Whether incumbent participation ultimately accelerates commercialisation or constrains the technology’s trajectory to paths compatible with existing supply chain architectures is a question with significant implications for market structure and the distribution of economic returns.

Consumer Acceptance: Scale, Heterogeneity, and the Theoretical Foundations of Adoption

If the economics of cultured meat are uncertain, the consumer acceptance literature is arguably more so. The range of acceptance estimates is striking: [91] synthesised studies reporting figures from 5% to 65%, a thirteen-fold spread that cannot be explained by population differences alone. Methodological variation — differences in how products are described, whether tasting occurs, what price is assumed, and how acceptance is operationalised — drives much of this dispersion. This makes cross-study comparison difficult and calls for greater methodological standardisation in future research. Further empirical disaggregation reinforces this variability: [16] found that while majorities of surveyed consumers expressed willingness to try cultured meat (54–66.4%), substantially fewer indicated willingness for regular consumption (24.5–55.2%), revealing a consequential gap between trial curiosity and habitual adoption.

However, methodological heterogeneity is not the only explanation for this spread; established technology adoption theory provides a complementary and arguably more analytically productive lens. Rogers’ Diffusion of Innovations framework — which remains the central theoretical pillar of innovation adoption research [92] — categorises potential adopters along a predictable distribution: innovators, early adopters, early majority, late majority, and laggards. Read through this lens, the 5–65% acceptance range maps not onto measurement noise but onto the adopter segments that different studies happen to capture. Surveys conducted among younger, urban, technology-receptive populations are likely sampling innovators and early adopters, producing acceptance rates at the upper end, while studies in populations with stronger traditional food norms capture segments further along the diffusion curve. Rogers’ framework further predicts that the perceived attributes of an innovation — its relative advantage, compatibility with existing practices, complexity, trialability, and observability — critically determine the rate and extent of diffusion [92, 93]. For cultured meat, compatibility poses a particular challenge: the product must be reconciled not only with dietary habits but with deeply held conceptions of what constitutes “real” food, a cultural threshold that varies substantially across populations [17]. The systematic literature review by [17] reinforces this point, documenting significant cross-national variation in acceptance and noting that most empirical research has concentrated on wealthy, high-meat-consuming nations with secular-rational cultural values, leaving the diffusion dynamics in other cultural contexts substantially underexplored.

Several patterns within this adoption landscape emerge with reasonable consistency. Psychological barriers, particularly neophobia, disgust responses, and perceptions of unnaturalness, function as the primary impediments to acceptance [91, 94]. These barriers have been given more precise theoretical grounding through the construct of food technology neophobia (FTN) — a validated psychometric measure distinct from general food neophobia that captures aversion specifically to foods produced through novel technological processes [95]. FTN has emerged as one of the strongest individual-level predictors of cultured meat rejection: [27], applying an extended Theory of Planned Behaviour (TPB) model to German consumers, found that food technology neophobia exerted a strong negative influence on attitudes toward cultured meat, while green consumption values exerted a countervailing positive influence. Their model explained 77.8% of the variance in consumption willingness, with perceived behavioural control emerging as the strongest predictor, followed by specific attitudes and subjective norms [27]. This finding is important because it identifies FTN not as a vague cultural sentiment but as a measurable psychological trait with demonstrated predictive validity — one that marketing and communication strategies must actively address rather than assume will dissipate with exposure. Research on consumer responses to analogous novel food technologies corroborates this pattern: food neophobia consistently exerts a significant negative effect on purchase intentions across diverse innovation contexts, including insect-based foods, 3D-printed food, and GMO products [93, 96, 97]. More broadly, the literature on consumer acceptance of new food technologies suggests that these aversive responses are not straightforwardly rational reactions to objective product characteristics; they operate as affect-driven heuristic filters shaped by perceptions of unnaturalness, low personal control, and moral intuitions about technological interference with food [31]. Critically, the information-deficit hypothesis — the assumption that consumer resistance will yield to better scientific communication — finds little empirical support; consumers tend to use new information to confirm prior beliefs rather than to update them rationally [31, 18]. Indeed, [18] found that technical information about laboratory production processes actually reduces acceptance, while benefit-oriented framing — particularly messages emphasising personal health advantages — improves it, and negative framing produces stronger attitudinal shifts than positive framing. These findings have direct implications for how producers and advocates communicate about cultured meat: information strategies must be carefully calibrated to audience psychology rather than simply increasing the volume of factual content.

Ethical and environmental motivations, by contrast, function as the strongest positive drivers of acceptance [91], suggesting that framing strategies emphasising sustainability credentials may be more effective than nutritional messaging for segments already motivated by these concerns. Emotional benefits — particularly the “warm glow” associated with animal welfare — have been identified as among the most powerful predictors of acceptance in experimental settings [89], and organisational trustworthiness significantly increases willingness to purchase, indicating that the credibility of the producing firm, not merely the product’s attributes, shapes consumer decisions [89]. Climate change concern has also been identified as a significant positive predictor of cultured meat consumption intention, reinforcing the importance of sustainability-oriented framing for environmentally motivated consumer segments [97].

Demographic variation is substantial and reasonably well-documented. Younger and more educated consumers show greater openness to cultivated meat [10, 16], with most in this segment expressing willingness to try the product regularly or use it as a conventional meat substitute — while willingness to pay a premium price is considerably narrower, with only approximately half of even receptive consumers prepared to do so [10]. The geographic and cultural dimension, though underdeveloped, is beginning to receive more systematic attention: [16] documented that the drivers of acceptance differ meaningfully across national contexts, with disgust predicting rejection most strongly in the United States, health and safety perceptions dominating in China, and ethical considerations carrying greater weight in India. Awareness itself varies substantially by region, with the highest levels reported in China and India and the lowest in Western European nations such as France [18]. Most empirical work has nevertheless been conducted in Western European, North American, and East Asian contexts, leaving consumption patterns and cultural food norms in low- and middle-income countries largely unstudied, despite these being the regions of greatest projected meat demand growth [17].

Perhaps the most counterintuitive finding in the consumer literature concerns dietary identity, and it is here that the Theory of Planned Behaviour offers its most illuminating explanatory contribution. [94] documented that meat eaters show greater interest in actually consuming cultivated meat than vegetarians or vegans do, even though the latter groups are more supportive of its production in principle. This paradox — termed the “vegan paradox” here — has significant implications for market segmentation, but it resists explanation if acceptance is modelled purely as a function of attitudes. The TPB decomposes behavioural intention into three components: attitudes toward the behaviour, subjective norms (perceived social expectations), and perceived behavioural control (the individual’s sense of capacity to perform the behaviour). For vegans and vegetarians, attitudes toward cultured meat as a concept may be positive, but subjective norms within their dietary communities actively discourage consuming animal-derived products — even those produced without slaughter — while their established behavioural identity as non-meat-eaters constitutes a form of perceived behavioural control that works against purchase intention. [28] provided a particularly incisive analysis of this phenomenon, arguing that what standard neophobia scales register as “food neophobia” among vegans actually reflects deep ideological and value-based commitments — moral consistency rather than fear of the novel. Vegetarians and vegans in their analysis expressed more positive perceptions of cultured meat than meat-eaters yet were less inclined to purchase it, confirming that positive perception does not predict commercial uptake when identity-level norms and behavioural commitments intervene [28]. For conventional meat eaters, by contrast, cultured meat represents an incremental substitution within an existing consumption category — high compatibility in Rogers’ terms [92] — rather than a category violation, producing the counterintuitive result that the population most resistant to changing its dietary behaviour is also the most receptive to this particular product. The implications for marketing strategy are substantial: the natural-seeming target audience of ethically motivated non-meat eaters is actually less likely to purchase the product than conventional meat consumers, who may view cultured meat as an acceptable variant of something they already eat. Effective commercialisation therefore requires reorienting market segmentation away from ethical-dietary identity and toward the psychographic profiles that diffusion theory identifies as predictive of early adoption: openness to technological innovation, low food technology neophobia [95, 27], and high perceived compatibility with existing consumption practices.

Price Sensitivity, Investment, and the Long-Term Trajectory

The sensitivity of consumer behaviour to price is made vivid by one particularly striking finding: when cultured beef and conventional beef are offered at the same price, only 5% of consumers choose the cultured option [91]. This challenges the assumption embedded in many commercialisation models that price parity is a sufficient condition for market penetration. It suggests that achieving cost competitiveness is necessary but not sufficient — consumer preference for the familiar product persists even at identical prices, pointing to the psychological barriers noted above as durable rather than merely transitional obstacles. Systematic reviews of the consumer acceptance literature corroborate this conclusion, consistently finding that negative attitudes, disgust responses, and naturalness concerns persist independently of price considerations [16, 18]. Read through the lens of technology adoption theory, this finding confirms that relative advantage, narrowly defined as cost equivalence, is insufficient to drive adoption when compatibility, observability, and perceived complexity remain unfavourable [31]. The extended Theory of Planned Behaviour, applied empirically to cultured meat in the German market, similarly demonstrates that subjective norms and moral attitudes exert influence on purchase intention above and beyond economic factors [27], reinforcing the view that non-price barriers are structurally embedded rather than incidental. Social trust in producing institutions — which correlates inversely with risk perception for novel food technologies [31, 89] — and the framing of product terminology itself further modulate willingness to purchase; [94] found that terms such as “pure meat” generate substantially more favourable responses than “lab-grown meat,” an effect that labelling regulations will either amplify or constrain. Bryant & Barnett’s [16] review similarly documents that naming conventions and information framing consistently shift stated purchase intent across multiple national contexts, underscoring the regulatory stakes of contested terminology decisions.

The investment landscape reflects both the opportunity and the risk. The startup ecosystem has attracted substantial venture capital, but IP fragmentation, proprietary media formulations, and the capital intensity of bioreactor infrastructure create structural challenges for smaller entrants [84, 87]. Investor perspectives from within the sector reveal an awareness of these structural tensions: agri-tech investors frequently cite regulatory uncertainty and the lack of shared infrastructure standards as key risk factors that suppress capital deployment into earlier-stage ventures [83]. Ethnographic research across cellular agriculture organisations has further documented that the sector is predominantly governed by traditional hierarchical ownership models underwritten by venture capital and defended through proprietary intellectual property strategies — an organisational logic that constrains the open knowledge-sharing environment on which cumulative industry-wide learning depends [40]. The rhetorical openness that cellular agriculture advocates frequently claim — appeals to democratising food production and disrupting agribusiness monopolies — sits in tension with the closed, proprietary structures through which the technology is actually being developed, with public engagement largely confined to media outreach and marketing rather than meaningful participation in governance [40]. The pharmaceutical biomanufacturing experience is instructive here: pre-competitive data sharing and industry-wide experience curve progression have been identified as critical accelerators of cost reduction in biologics, and the absence of analogous knowledge-sharing mechanisms in the cultured meat sector may slow the rate at which cumulative production experience translates into lower costs [20, 19]. Labelling and naming conventions — whether products can be called “meat,” “chicken,” or require qualifier terms — remain contested regulatory questions with direct implications for purchase intent [18, 16], and while empirical evidence on jurisdiction-specific regulatory outcomes remains thin, the direction of effect is consistent across consumer studies.

The literature as of 2025 presents a field that has matured considerably in its technical specificity [11, 88] while still relying heavily on theoretical models rather than empirical data from operating pilot-scale facilities. The combination of wildly variable cost projections, uncertain consumer acceptance, and regulatory heterogeneity across jurisdictions means that commercialisation trajectories remain genuinely difficult to forecast. Longitudinal consumer studies — ideally grounded in validated theoretical frameworks such as the TPB [27] and Rogers’ diffusion model [31] to enable cumulative knowledge-building across contexts — rigorous cost data from actual production operations, and systematic analysis of acceptance in underrepresented markets represent the most important gaps for future research to address.

7. Sustainability Assessment, Environmental Impact, and Nutritional Comparison

Sustainability assessment of cultured meat has emerged as one of the most contested areas within the broader alternative protein literature, evolving from early optimism toward a more nuanced and sometimes sobering appraisal of environmental credentials, nutritional parity, and comparative performance against rival protein sources. The trajectory of this scholarship reveals a field in productive tension: initial enthusiasm generated by industry-proximate life cycle assessments has been progressively tempered by independent critical scrutiny, while nutritional and technofunctional evaluations have complicated simplistic equivalence claims. Understanding how this reassessment has unfolded is essential for situating the current state of knowledge and identifying where genuine scientific consensus ends and speculative projection begins.

Life Cycle Assessment: Emissions, Land, and Water

Early sustainability discourse around cultured meat was dominated by headline figures that appeared, at first glance, to make the environmental case self-evident. Cultured meat requires 82–96% less water and occupies approximately 1% of the land area demanded by conventional livestock production [72]. These resource-use advantages, particularly land sparing, have been consistently cited as among the most compelling reasons to pursue cellular agriculture [78, 76]. Full-system modelling supports the scale of these gains: a complete transition to cellular agriculture could reduce agricultural land use by as much as 83% and cut food-system greenhouse gas emissions by 52%, primarily by eliminating pasture and drastically reducing feed-crop demand [1]. By the early 2020s, land and water efficiency had become near-axiomatic sustainability selling points, repeated across reviews and perspectives as though the overall environmental calculus had been settled [91].

However, the energy dimension complicated this picture substantially. Cultured meat production demands up to four times more direct energy input than conventional livestock systems [72], and full-transition scenarios project food-system energy demand growing by 69–83% depending on the renewable source employed [1]. This is not a peripheral caveat but a structural feature of the technology: maintaining sterile bioreactor environments, supporting cell proliferation, and producing complex growth media all impose substantial thermodynamic costs that conventional pasture or feedlot systems do not. Facility energy — dominated by active cooling, which can account for approximately 75% of in-facility electricity use — and culture-medium ingredient production constitute the two primary environmental hotspots in ex-ante life cycle assessments of commercial-scale production [2]. The implication is that the net greenhouse gas benefit of cultured meat is not intrinsic to the technology but is entirely contingent on the carbon intensity of the energy supply powering production: carbon footprints range from under 3 kg CO₂-eq/kg with fully renewable electricity to over 14 kg CO₂-eq/kg under average global energy mixes [2]. This dependency was recognized in early technical reviews [78] but has become the central organizing concern of more recent critical work.

The Renewable Energy Dependency Problem

The critique crystallized most sharply in more recent scholarship. A 2025 critical review synthesizing the latest production data concluded that many sustainability claims made by the cultured meat industry are overly ambitious and lack evidence-based support, with environmental footprint improvements fundamentally dependent on the transition to renewable energy sources [98]. This finding reframes the debate: cultured meat’s sustainability is not an engineering achievement already banked but a conditional future state whose realization depends on factors largely external to the industry itself, namely regional grid decarbonization timelines and the availability of dedicated renewable capacity for industrial food production. Modelling that accounts for current grid energy mixes consistently finds that a transition to cellular agriculture may actually increase energy consumption relative to conventional livestock production, even as it reduces land use and certain categories of greenhouse gas emissions [1].

This has profound implications for life cycle assessment methodology. Early LCAs, many of which were conducted at theoretical or conceptual scales rather than based on actual pilot-scale production data, projected emissions reductions under idealized energy scenarios [3]. Independent reviews have increasingly flagged these assessments as methodologically insufficient, noting that they frequently omit upstream impacts from growth media supply chains, including the energy-intensive synthesis of recombinant proteins and pharmaceutical-grade amino acids [98, 82]. More rigorous ex-ante assessments of commercial-scale production — modelling projected 2030 facilities — confirm that emissions performance remains acutely sensitive to the assumed energy source, with renewable-powered scenarios yielding substantially lower global warming potential than fossil-fuel-dependent ones [2]. The scalability gap compounds the problem: current cultured meat production capacities remain orders of magnitude below those of conventional meat industries, and techno-economic analyses indicate that bioreactor scale-up introduces non-linear cost and energy intensity dynamics that small-scale models systematically underestimate [44], meaning that real-world sustainability projections extrapolated from laboratory or small bioreactor conditions are, at best, highly speculative [82, 79].

The energy dependency problem also carries a justice dimension that the sustainability literature has been slow to address. Since access to renewable energy infrastructure is itself distributed inequitably across the Global North/South divide — a structural asymmetry reinforced by historical patterns of industrial investment [40] — cultured meat’s conditional environmental benefits are geographically constrained in ways that compound existing inequalities: nations least responsible for industrial animal agriculture’s environmental harms, and least able to finance renewable energy transitions, would bear the costs of a cellular agriculture-led food system shift without accessing its benefits [41]. This distributional concern — discussed more fully below in the context of political economy — adds an equity dimension to what might otherwise appear to be a purely technical question about energy sourcing.

Nutritional Composition and Technofunctional Properties

Parallel to the environmental debate, a separate but related question concerns whether cultured meat can genuinely replicate the nutritional and physical properties of conventional meat. Here the evidence is mixed and context-dependent. A 2025 perspective reported that cultivated meat achieves protein and fat levels broadly comparable to chicken and pork, and in some formulations exhibits higher mineral content than conventional equivalents [88]. These findings have been cited in support of nutritional parity claims and have fueled optimism that the product could serve as a functional dietary substitute.

However, more cautious analyses complicate this picture. A 2022 review of nutritional, technofunctional, and sensorial properties concluded that cultured meat differs meaningfully from conventional meat across all three dimensions, with deficiencies particularly evident in texture, fat distribution, and structural complexity [79]. The architecture of conventional muscle tissue — with its intramuscular fat depots, myofibrillar structure, and connective tissue scaffolding — arises from developmental and physiological processes that in vitro cell culture does not yet replicate [48, 13]. Achieving the fat marbling that governs flavor and mouthfeel in beef, for instance, requires the co-culture of adipocytes within three-dimensional tissue constructs, a technical challenge that remains largely unresolved at scale [79, 82]. Recent work has demonstrated proof-of-concept approaches — including the integration of bovine mesenchymal stem cell-derived adipocytes within alginate hydrogel scaffolds to produce marble-like fat-muscle constructs — but reported differentiation efficiencies of only approximately 10–45%, and organoleptic validation at commercially relevant scales remains outstanding [99]. Micronutrient bioavailability adds a further layer of uncertainty, since mineral content as measured in compositional analyses does not directly predict physiological uptake [100], and long-term human nutritional studies using cultured meat products as a dietary staple do not yet exist.

Comparative Assessment Across Alternative Protein Categories

Situating cultured meat within the broader alternative protein landscape reveals further complexity. Plant-based approaches benefit from mature supply chains and substantially lower production costs — plant proteins cost 3.8 to 12.7 times less than livestock protein at the raw ingredient level — but require intensive processing to approximate meat-like textures and flavors, processing that itself has nutritional and environmental consequences [76]. Plant-based meat products accordingly carry higher retail prices, driven by processing rather than raw material costs, while cultured meat remains economically unviable at commercial scale under most cost scenarios [76, 82]. The comparison with insect-based and fermentation-derived proteins involves further methodological challenges, as existing LCA studies differ substantially in functional units, system boundaries, and allocation methods [3, 2], with no comprehensive head-to-head LCA using harmonized boundaries currently available across all categories.

The microbial single-cell protein (SCP) literature offers an additional comparative dimension. Bacteria achieve the highest reported protein contents among microorganisms at 50–80% of dry weight, followed by microalgae (45–64%), yeasts (24–54%), and filamentous fungi (15–45%), with growth rates far exceeding those of any livestock species [101]. Contemporary SCP development is distinguished by its explicit integration with circular economy principles, systematically exploring agricultural residues and food processing effluents as fermentation substrates that simultaneously produce protein and valorise waste streams [101]. However, SCP faces its own translational constraints — nucleic acid accumulation that can elevate serum uric acid in consumers, cell wall digestibility limitations that reduce protein bioavailability, and sensory engineering challenges — suggesting that no single alternative protein technology currently offers an unqualified advantage across all relevant performance dimensions [101, 82].

The sustainability context for cultured seafood deserves separate consideration. Wild fish stocks face documented collapse projections, with some analyses suggesting that continued overexploitation, compounded by climate change and pollution, could eliminate commercially viable wild fisheries by 2048 [54]. With fish supplying approximately 17% of global animal protein and representing a critical nutritional lifeline for over three billion people [54], cell-based fish production carries urgency that may not apply equally to terrestrial meat substitutes. Cellular aquaculture research has accordingly begun to address fish-specific bioprocessing challenges, including the differentiation of marine muscle and fat cell lineages under conditions distinct from mammalian cell culture [53]. The environmental baseline for cultured seafood comparison is thus not conventional feedlot production but an ecologically deteriorating wild-capture fishery, potentially shifting the calculus in favor of cellular aquaculture even under energy-intensive production scenarios.

Methodological Limitations and Outstanding Questions

What emerges from this body of literature is a picture of a technology whose sustainability promise is real in principle but empirically undersubstantiated in practice. The field’s foundational LCAs were largely theoretical, often conducted with industry involvement, and frequently excluded key upstream processes [98, 78]. Subsequent independent reviews have not overturned the core resource-use advantages — the land and water savings appear robust [1, 102] — but have substantially narrowed and conditionalized the greenhouse gas narrative [98, 91, 2, 3]. Nutritional assessments similarly remain limited by the absence of bioavailability data and long-term health outcome studies [79, 81]. The most significant gap cutting across all sub-themes is the absence of comprehensive, independently verified LCAs grounded in actual pilot-scale production data, incorporating full media supply chain impacts and tested against plausible rather than idealized energy scenarios. Until such data are available, the sustainability case for cultured meat rests on conditional projections rather than demonstrated performance — a distinction that responsible scholarship must sustain clearly.

Taken together, the LCA and nutritional evidence as of 2025 supports a measured rather than optimistic verdict: cultured meat offers credible resource-use advantages in land and water, but its greenhouse gas credentials remain genuinely conditional, and its nutritional equivalence to conventional meat is incompletely established [79, 82]. Crucially, the renewable energy dependency problem does not sit alongside the economic viability challenge — it is embedded within it. The energy-intensive requirements of sterile bioreactor operation and growth media synthesis are simultaneously the source of cultured meat’s elevated carbon footprint and a primary driver of its prohibitive production costs [43, 45, 44]; decarbonizing the production process and reducing its cost are therefore not separable objectives but two facets of the same engineering and infrastructure challenge [3, 46]. These environmental uncertainties accordingly compound rather than stand apart from the production-cost and regulatory obstacles examined in preceding sections, and it is against this multiply conditional backdrop — biological, economic, regulatory, and now environmental — that the Discussion turns to assess what the field’s collective progress to date genuinely implies for commercialisation trajectories and research priorities.

8. Discussion

The past three years have fundamentally reoriented how researchers, regulators, and industry actors understand the cultured meat challenge. What was once framed primarily as a biological problem — can cells be grown outside the animal? — is now understood as a systems integration problem, where biology, engineering, economics, regulation, and consumer psychology must converge simultaneously. This review’s synthesis across five thematic clusters reveals that progress in each domain has been uneven, and that the most consequential bottlenecks have shifted in ways that carry significant implications for both research strategy and commercialization timelines. Moreover, the integration of sociotechnical transitions theory and political economy perspectives into this assessment reveals a dimension of the viability challenge that techno-economic analysis alone cannot capture: the institutional, political, and structural conditions that will ultimately determine whether laboratory achievements translate into regime-level food system change.

The Cost-Biology Nexus Has Become Central

Perhaps the clearest consensus shift emerging from recent literature is that cell culture media — specifically the elimination of fetal bovine serum and its replacement with cost-effective, animal-free alternatives [30] — now sits at the intersection of every other challenge. Media formulation is simultaneously a biological question (which growth factors maintain proliferative capacity and myogenic differentiation?), an economic question (recombinant albumin and growth factors can constitute over 90% of production cost at current prices [43, 44]), and a regulatory question (undefined serum-based media are increasingly untenable under emerging food safety frameworks [57, 11]). The 2024–2025 literature has moved substantially beyond proof-of-concept serum-free formulations [52, 62] toward systematic optimization — including recombinant expression of key mitogens and plant-derived hydrolysate substitutes [61] — yet standardized benchmarking protocols that would allow cross-laboratory comparison remain absent. This gap is not merely academic: without reproducible performance data, neither investors nor regulators can assess whether claimed cost reductions are generalizable or laboratory-specific.

Engineering Progress Is Real but Incomplete

Bioreactor and scaffolding research has matured considerably, with stirred-tank, hollow-fiber, and perfusion systems all demonstrating credible paths to scale [46, 15]. However, the review reveals a persistent gap between benchtop demonstration and pilot-scale validation [44]. The field effectively has two parallel literatures — one proving biological feasibility at small scale, another modeling economic viability at industrial scale — with limited empirical data bridging them.

The pharmaceutical biomanufacturing literature provides a sobering but instructive reference point for evaluating this gap. In biologics manufacturing, the transition from demonstrated bench-scale feasibility to routine industrial operation has historically required decades of sustained investment, even with regulatory frameworks, capital markets, and institutional expertise already in place. The progression from early demonstrations of integrated continuous processing [73] through pragmatic intensification strategies such as N-1 perfusion seeding [36] to the recent convergence of advanced process control and regulatory enablement [20, 74] traces a maturation arc that cultured meat has barely begun to traverse. Critically, the pharmaceutical precedent reveals that process intensification is a multivariate challenge: individual improvements in cell density, media composition, or bioreactor configuration must be co-optimised to deliver their full cost benefit, a finding demonstrated empirically when high-density seeding without corresponding media reformulation failed to raise final titers in CHO cell culture [36]. The cultured meat field’s current tendency to report advances in media, scaffolding, and bioreactor design as isolated achievements — rather than demonstrating their combined performance in integrated production systems — mirrors an early stage of pharmaceutical process development that the biologics sector has since moved beyond.

Scaffolding research presents a related structural problem: most published work evaluates scaffold biocompatibility or cell adhesion in isolation [13, 48], while systematic data on how degradation kinetics affect sensory texture in the final product remain scarce. The design requirements are demanding — scaffolding materials should ideally contribute less than five percent of total production costs and degrade within two to three weeks unless integrated into the final product [13] — yet empirical validation of these targets at scale is largely absent from the literature [10]. This matters because the unstructured-to-structured product gap is itself an under-discussed commercialization constraint. Minced and nugget formats, while technically accessible, do not command the price premiums that whole-cut products would [70, 43], limiting the economic pathway for early-stage producers.

Biomanufacturing Precedents and the Question of Timeline

The integration of pharmaceutical and industrial biomanufacturing evidence into the cultured meat cost discussion fundamentally reframes the question of when — not merely whether — economic viability can be achieved. The monoclonal antibody manufacturing trajectory, in which cost-of-goods fell by orders of magnitude over approximately two decades through the compounding interaction of learning curves, economies of scale, and process intensification [19, 20], demonstrates that dramatic cost reduction in biological manufacturing is empirically documented rather than merely theoretically possible. However, several structural features of the pharmaceutical experience caution against assuming that cultured meat will traverse an equivalent cost curve on a compressed timeline.

First, the pharmaceutical industry’s cost reductions were driven substantially by downstream purification optimisation and the development of standardised platform processes — particularly the convergence on Protein A chromatography for monoclonal antibodies — that enabled knowledge and efficiency to accumulate across products and facilities [19, 86]. Cultured meat lacks any equivalent platform standardisation: cell sources, media formulations, bioreactor configurations, and scaffold materials remain highly heterogeneous across producers [51, 9], inhibiting the cumulative learning that experience curve theory predicts should accelerate cost decline. The absence of pre-competitive data sharing mechanisms in the cultured meat sector — in contrast to the pharmaceutical industry, where organisations such as the Biotechnology Innovation Organization have facilitated benchmarking and best-practice dissemination — further constrains the rate at which industry-wide experience can accumulate [20]. The diversity of media formulations alone illustrates this fragmentation: serum-free media development efforts remain largely proprietary and product-specific [52, 30], preventing the kind of convergent optimisation that drove efficiency gains in biopharmaceutical cell culture.

Second, the capital intensity of bioreactor infrastructure creates path dependencies that are difficult to reverse. The pharmaceutical sector’s experience with the retrofit economics problem — nearly all documented cost advantages of continuous manufacturing assume greenfield facility design, while the installed manufacturing base is predominantly batch-configured — applies directly to cultured meat, where early facility investments made under current technological assumptions may become suboptimal as the field matures [33, 103]. Techno-economic modelling of cultivated meat production illustrates how acutely this matters: moving from 42,000 L to 262,000 L bioreactor configurations reduces cost-of-goods-sold from approximately $35/kgto$17/kg at an industry output of 100 million kilograms per year, meaning that early facilities built at suboptimal scale lock in substantial cost disadvantages [44]. For a nascent industry with limited capital reserves, the risk of technology lock-in is acute.

Third, and more favourably, cultured meat’s status as a food product rather than a therapeutic substantially alters the purity requirements that drive a large share of pharmaceutical manufacturing cost. The absence of chromatographic purification, the tolerance for compositional heterogeneity, and the elimination of costly quality assurance regimes designed for injectable products could, in principle, compress the relevant sections of the cost curve significantly. If upstream productivity can be raised to levels approaching those achieved in optimised CHO cell fed-batch culture — where titers have progressed from milligrams to over 10 g/L through systematic co-optimisation of cell line, media, and feeding strategy [35] — the combination of lower purity requirements and high volumetric output could enable cost trajectories meaningfully faster than the pharmaceutical precedent. The crucial unknown is whether mammalian cells cultivated for food, which must produce tissue mass rather than secreted protein, can achieve analogous productivity improvements through comparable process engineering strategies. The CHO cell optimisation literature demonstrates that temperature downshifting, dynamic feeding, and metabolic flux analysis can dramatically enhance cell-specific productivity [35], but whether these levers translate to the distinct metabolic context of myogenic and adipogenic differentiation remains untested at production scale.

The most credible reading of the combined evidence is that cultured meat’s cost reduction trajectory will be neither as slow as the full pharmaceutical timeline nor as fast as the most optimistic industry projections imply. The food-grade production context removes certain cost floors that constrain biologics, but the absence of platform standardisation, the negligible cumulative production base, and the early state of process integration impose their own tempo. Achieving production costs in the range of $10–20perkilogram—atargetthatseveraltechno-economicanalysessuggestisnecessaryforpremiummarketentry,andwhichmodellingindicatesrequiresmediacoststofalltoapproximately$0.75 per litre alongside deployment of the largest feasible bioreactor configurations [44, 45] — likely requires a decade or more of sustained investment, process intensification, and coordinated learning, conditional on continued progress in serum-free media cost reduction and bioreactor scale-up.

Cultured Meat as a Sociotechnical Niche: Transition Dynamics and Regime Resistance

The techno-economic analysis presented above, while essential, captures only one dimension of the viability challenge. Sociotechnical transitions scholarship provides a complementary and arguably indispensable analytical framework for understanding why the pathway from demonstrated technical feasibility to commercially significant market presence is so much longer and more contested than production cost curves alone would predict.

The multi-level perspective (MLP) situates cultured meat as a niche innovation contesting one of the world’s most deeply entrenched sociotechnical regimes: the global livestock system [21, 22, 23]. The livestock regime’s persistence is sustained not by economic efficiency alone but by the interlocking alignment of regulatory frameworks, subsidy structures, supply chain architectures, consumer habits, cultural meanings, and political coalitions that together generate powerful path dependency. Systematic review of MLP applications to agriculture and food systems has confirmed that agri-food regimes operate differently from the energy and transport systems for which the framework was originally developed — niches tend to be constituted by alternative systems rather than protected innovation spaces, and the risk that scaling up niche innovations dilutes their transformative intent is particularly acute when incumbent corporations absorb and reposition novel technologies within existing market logics [24].

This theoretical lens illuminates three categories of dynamics that are operating simultaneously on cultured meat’s trajectory:

Landscape pressures — the exogenous macro-contextual forces that destabilise established regimes — are genuinely favourable to cultured meat. Climate change mitigation imperatives, documented threats to wild fishery collapse [54], growing public concern over antibiotic resistance in industrial livestock — where it is estimated that over 70% of medically important antibiotics globally are consumed by food animals, accelerating the emergence of resistant pathogens [58, 81] — and pandemic-related awareness of zoonotic disease risk all erode the external legitimacy of conventional animal agriculture. These pressures create the windows of opportunity that MLP theory identifies as necessary — though not sufficient — preconditions for transition [26].

Regime vulnerabilities are accumulating but have not yet reached the multi-dimensional destabilisation threshold that historical precedent suggests is necessary for genuine transition. Longitudinal analysis of the British coal industry’s decline between 1913 and 1967 demonstrated that regime collapse requires the simultaneous erosion of financial resources, external legitimacy, and internal cognitive commitment among industry actors — a convergence that took decades even under sustained competitive and regulatory pressure [26]. The conventional livestock industry currently faces external legitimacy challenges on environmental and welfare grounds but retains formidable financial resources, deep institutional relationships with regulators, and strong internal cognitive commitment. Its organised political response — documented through discourse network analysis revealing two hardened advocacy coalitions in the United States cellular agriculture policy subsystem, with the pro-animal agriculture coalition deploying institutional resources that extend well beyond media-visible arenas [25] — is symptomatic of precisely the kind of active regime defence that transition theory identifies as capable of prolonging incumbent persistence well beyond what economic fundamentals would predict.

Niche-internal dynamics — the processes of learning, network building, and expectation management within the cultured meat innovation community itself — present a more mixed picture. On the positive side, the field has achieved significant technical learning across media development, bioreactor design, and scaffold engineering. On the negative side, the innovation system remains geographically concentrated in a small number of wealthy nations — with the United States, Israel, and Singapore accounting for the large majority of both venture investment and firm foundings [7, 83] — institutionally fragile, and organisationally dominated by venture capital-backed proprietary structures that inhibit the open knowledge accumulation on which both experience curve progression and legitimate governance depend [40, 41]. The narrative infrastructure of cellular agriculture — characterised by one critical analysis as “recombinant ecomodernism” deploying craft-production aesthetics to domesticate anxieties about biotechnological unnaturalness while simultaneously obscuring questions about labour displacement, corporate co-optation, and intellectual property concentration [104] — reveals a niche whose public legitimation strategy is sophisticated but whose internal governance arrangements have not kept pace with its rhetorical claims to democratisation.

This MLP reading has a direct implication for how the field understands platform standardisation and pre-competitive data sharing — two mechanisms this review has identified as critical for accelerating cost reduction but has not yet theorised in structural terms. Innovation systems research provides the analytical vocabulary: in the pharmaceutical sector, pre-competitive data sharing and industry-wide benchmarking functioned not merely as efficiency mechanisms but as institutional infrastructure that enabled cumulative learning to propagate across the industry rather than remaining trapped within individual firms [20, 19]. The cultured meat sector currently lacks this institutional infrastructure. Ethnographic research has documented that the sector’s venture capital-driven organisational logic actively works against open knowledge sharing, with proprietary intellectual property strategies defended as conditions of funding and competitive positioning [40]. The result is a structural tension between what experience curve theory predicts would accelerate cost reduction — open, cumulative, industry-wide learning — and what the sector’s dominant organisational forms incentivise — closed, firm-specific knowledge capture. Resolving this tension is not a matter of exhortation but requires deliberate institutional design: the creation of pre-competitive consortia, open-source biological protocol platforms, and shared benchmarking standards that can function within — or alongside — the proprietary commercial structures that currently govern the field. The pharmaceutical industry’s experience suggests that such institutional infrastructure, once established, can coexist productively with competitive commercial dynamics, but it typically requires either public funding, industry association coordination, or regulatory encouragement to emerge [20].

Economic Viability as a Political-Institutional Achievement

Perhaps the most consequential insight that emerges from integrating political economy and transitions perspectives into this review’s techno-economic analysis is that economic viability is not purely a function of production cost reduction. It is co-determined by the political and institutional environment in which the technology must compete — an environment that is itself actively shaped by both incumbent and challenger interests.

This proposition has several concrete dimensions. First, the subsidy structures that underpin conventional livestock production — including feed subsidies, water access pricing, and environmental cost externalisation — establish a competitive baseline that cultured meat must match not on the basis of true cost comparison but against an artificially depressed incumbent price [91, 76]. The failure of technology disruption forecasts predicting rapid livestock displacement [90] is partly attributable to this structural asymmetry: S-curve models that treat incumbent costs as market-determined rather than policy-supported systematically underestimate the difficulty of achieving competitive parity. True-cost accounting frameworks that attempt to internalise environmental externalities — including greenhouse gas emissions, land degradation, and water use — consistently reveal that the retail price of conventional meat significantly understates its full social cost [91], making the apparent price gap between conventional and cultured products a policy artefact as much as a reflection of genuine production efficiency differences.

Second, the regulatory environment is not a neutral adjudicatory space through which the best technology passes on merit; it is a contested institutional terrain where incumbent and challenger coalitions actively seek to shape rules in their favour. The discourse coalition analysis documenting two polarised advocacy groups in the U.S. cellular agriculture policy subsystem — with battle lines hardened well before any mature regulatory framework exists [25] — makes clear that regulatory outcomes will reflect political bargaining as much as scientific assessment. Labelling disputes, where incumbent agricultural interests invest significant resources in restricting cultured meat’s access to conventional meat terminology, are not peripheral nomenclature debates but proxy contests over market legitimacy with direct commercial consequences [79, 11]. Several U.S. states have enacted or proposed legislation explicitly prohibiting the use of terms such as “meat” or “beef” for cell-cultured products, illustrating how legislative channels are mobilised as competitive instruments by incumbent industries [25].

Third, the geographic concentration of cultured meat innovation in wealthy nations raises justice and equity concerns that, if unaddressed, could generate political opposition in precisely the markets where alternative proteins might deliver their greatest food security benefits. Current development patterns — investment concentrated in the United States, Israel, Singapore, and parts of Europe, with the Global South positioned primarily as a downstream consumer of technologies developed elsewhere [41] — risk reproducing the same power asymmetries that characterise the incumbent food system, undermining the legitimacy of a transition claimed to be in the global public interest. Investor perspectives likewise confirm that commercial logic currently orients cellular agriculture toward premium markets in high-income countries, further entrenching the geographic skew [83]. The justice framework applied by recent scholarship identifies deficits across distributional, procedural, and recognitional dimensions: the economic gains from cellular agriculture accrue to those already holding capital; communities most affected by food system transformation have minimal voice in shaping the technology’s trajectory; and the cultural and economic significance of animal agriculture to particular communities is systematically underweighted in advocacy narratives [41].

These political-institutional dimensions do not merely add complexity to the economic viability question; they fundamentally redefine it. A cultured meat product that achieves $17perkilogramproductioncostinajurisdictionwhereconventionalmeatissubsidisedto$5 per kilogram retail, where labelling regulations prohibit the term “meat,” and where incumbent industry coalitions have secured precautionary regulatory requirements that add years to market entry timelines, is not economically viable regardless of its technical achievement. Conversely, a product that achieves only modest cost reductions but operates within a regulatory environment that provides clear approval pathways, permits informative labelling, and internalises the environmental costs of conventional production may achieve commercial traction at higher absolute price points. Economic viability, in short, is as much a governance achievement as a manufacturing one.

Regulatory Divergence Is a Feature, Not a Bug — For Now

Regulatory heterogeneity across the US, EU, Singapore, and China is often framed as a problem for global commercialization, but this review’s synthesis suggests a more nuanced reading. Singapore’s Food Agency made history in late 2020 by granting the first market approval for a cultured chicken product, employing a three-step safety evaluation covering input materials, production controls, and compliance with food standards [11]. The US FDA/USDA joint framework, under which UPSIDE Foods completed a full dual-agency review by June 2023 to become the first company to receive a USDA grant of inspection for cultivated chicken [11], has together with Singapore’s precedent generated practical data — on safety dossier structure, novel food categorization, and post-market surveillance design — that is actively informing regulatory design in jurisdictions still developing their frameworks. The EU, by contrast, applies its Novel Foods Regulation requiring lengthy EFSA scientific assessments, with no approvals yet granted, illustrating how divergent timelines and definitions compound the burden on producers [11, 81]. The genuine risk is not divergence per se, but divergence without dialogue: if harmonization efforts stall, producers face costly market-by-market approval processes that disproportionately burden smaller innovators. The absence of mutual recognition agreements or even shared safety assessment methodologies represents one of the field’s most consequential unresolved governance questions [57], and one that the scientific community can contribute to by producing the long-term human consumption safety data that regulators across all jurisdictions currently lack.

The political economy analysis adds a further layer to this reading. Regulatory divergence is not merely an unintended consequence of different institutional traditions; it is, in part, a strategic outcome of incumbent industry action. Where conventional agricultural interests hold greater political influence — as in jurisdictions where livestock production constitutes a significant share of rural employment and export revenue — regulatory frameworks tend toward greater precaution, longer approval timelines, and more restrictive labelling requirements [25]. The literature on regime destabilisation suggests that this pattern will persist until the multi-dimensional erosion of incumbent legitimacy — financial, reputational, and cognitive — reaches a threshold at which political defence becomes unsustainable [26]. The implication for cultured meat firms and advocates is that regulatory strategy cannot be separated from political strategy: building coalitions, generating credible safety evidence, and engaging proactively with the distributional concerns of affected agricultural communities are not supplements to the regulatory process but preconditions for its favourable resolution.

Consumer Psychology Demands Theoretical Rigour, Not Just Empirical Cataloguing

The consumer acceptance literature has accumulated a substantial body of empirical findings — heterogeneous acceptance rates, persistent neophobia, the vegan paradox, geographic variation — but has, until recently, lacked the theoretical scaffolding to render these findings cumulatively productive. This review’s integration of Rogers’ Diffusion of Innovations [92] and the Theory of Planned Behaviour [27] into the empirical landscape reveals that many apparently puzzling findings become predictable once adoption is modelled as a process shaped by perceived innovation attributes, social norms, and behavioural identity rather than attitudes alone. The vegan paradox, for instance, ceases to be counterintuitive when subjective norms and perceived behavioural control are distinguished from attitudes. Similarly, the wide acceptance range across studies becomes interpretable as reflecting which adopter segments are being sampled rather than mere methodological noise. Illustrating the explanatory power of this approach, Dupont et al. [27] applied an extended TPB model to a German consumer sample and found it explained 77.8% of the variance in willingness to consume cultured meat — with perceived behavioural control emerging as the strongest positive predictor and food technology neophobia as the most influential negative predictor, operating on both attitude formation and behavioural intention directly. Subjective norms, notably, were the weakest predictor, helping to explain why pro-environmental identity does not straightforwardly translate into acceptance. For the field to move from descriptive cataloguing toward predictive capacity — essential for informing commercialisation strategy — future consumer research should be grounded in these validated theoretical frameworks and designed to enable cross-study comparison through standardised measures, particularly of food technology neophobia [28, 27] and the core TPB components.

Environmental Claims Require Recalibration

The sustainability literature has undergone a significant consensus correction. Earlier lifecycle analyses that positioned cultured meat as unambiguously superior to conventional beef on climate metrics have given way to more conditional assessments [3, 2]. Energy source and grid decarbonization trajectory now emerge as decisive variables: cultured meat produced on carbon-intensive electricity grids may deliver worse long-term climate outcomes than ruminant production under some warming scenarios, due to differences in greenhouse gas persistence. This finding is reinforced by modelling showing that complete transition to cellular agriculture would increase total food system energy demand by 69–83% depending on renewable source, and that meaningful emissions reductions — projected at up to 52% system-wide — are contingent on powering production with renewable electricity [1]. Similarly, land-use assessments reveal that relying exclusively on agricultural feedstock for cultured meat offers limited environmental advantages over conventional meat production, with some scenarios showing comparable or marginally worse emissions intensities when crop rotation constraints and energy demands are fully accounted for [102]. These findings have not fully penetrated industry communication or policy discourse, creating a credibility risk if overclaiming is subsequently contradicted by independent assessment. They also reframe the sustainability case for cultured meat from a present-day certainty to a future contingency, one dependent on energy transition timelines that are outside the sector’s control. The socio-techno-ecological critique of existing transitions frameworks — which argues that ecological systems function as active and dynamic agents rather than passive background context [105] — suggests that adequate sustainability assessment of cultured meat requires integrating ecological dynamics as co-constitutive forces rather than treating them merely as landscape-level pressures that motivate transition. Whether the field develops analytical frameworks capable of this integration will significantly determine the credibility of its environmental claims.

Implications for Research Priority and Field Coordination

Taken together, these findings argue for a reallocation of research attention toward several underprioritized areas. First, species diversification — the field’s heavy concentration on bovine cells leaves poultry, porcine, and aquatic species substantially undercharacterized [50, 72], limiting market breadth and leaving nutritional and textural questions for many target products unanswered. The dominance of bovine satellite cell systems in the published literature [52, 9] means that cell isolation, expansion, and differentiation protocols for non-bovine species remain at comparatively early stages of development. Second, integrated systems research that tests scaffolding, bioreactor, and media configurations as combined production units rather than isolated components, generating the pilot-scale data that currently separates modeling from manufacturing reality. Third, longitudinal safety and genetic stability studies, particularly for immortalized cell lines, where data beyond approximately 120 population doublings are largely absent from the published literature [51, 58, 57] — a gap that will eventually constrain regulatory approval regardless of progress elsewhere. Fourth, the deliberate transfer of process engineering knowledge from pharmaceutical biomanufacturing — including experience curve methodology, integrated cost modelling frameworks, process intensification strategies such as N-1 perfusion seeding [36], and advanced process control architectures — into the food-grade cellular agriculture context. The pharmaceutical sector’s documented progression from batch to continuous manufacturing, spanning technical proof-of-concept through pragmatic intensification strategies to regulatory harmonisation [103, 36, 20], provides a roadmap that the cultured meat industry need not reinvent from first principles. Fifth, the establishment of pre-competitive data sharing and benchmarking consortia, modelled on mechanisms that have accelerated experience curve progression in pharmaceutical biomanufacturing, to enable industry-wide learning that proprietary fragmentation currently inhibits. The innovation systems literature makes clear that such consortia function not merely as efficiency mechanisms but as institutional infrastructure essential for enabling cumulative learning to propagate across an industry — infrastructure that the cultured meat sector’s dominant venture capital-driven organisational forms currently work against [40, 20, 83]. Establishing such infrastructure may require public funding, regulatory encouragement, or the deliberate creation of open-source biological protocol platforms that can coexist with proprietary commercial structures [11]. Sixth, sustained empirical engagement with the political economy of the protein transition — including longitudinal tracking of regulatory outcomes against incumbent industry lobbying, comparative analysis of how different governance arrangements shape innovation trajectories across jurisdictions, and participatory research that centres the perspectives of communities most affected by food system transformation, including livestock-dependent rural economies in both the Global North and South [41, 25].

The field stands at a productive but precarious inflection point: technically more capable than it was three years ago, economically still unproven at scale, and navigating regulatory environments that are developing faster than the safety evidence base supporting them [11, 57] — while simultaneously confronting organised political opposition from incumbent industries whose institutional resources and cognitive commitment to existing practices should not be underestimated. Coordinated, cross-disciplinary research that treats these dimensions as mutually constraining rather than sequentially addressable is the clearest path forward. The sociotechnical transitions literature’s central insight — that system innovations require simultaneous transformation across technology, regulation, infrastructure, user practices, and cultural meanings [22, 21] — applies with particular force to cultured meat, where no single domain of progress, however impressive, will prove sufficient in isolation.

9. Conclusions

This systematic review synthesized the current state of cultured meat research across four critical dimensions: production economics, technical development, regulatory governance, and market readiness, supplemented by cross-disciplinary analysis of cost reduction precedents in pharmaceutical and industrial biomanufacturing and by sociotechnical transitions and political economy scholarship that situates cultured meat’s trajectory within the structural dynamics of agri-food system transformation. Together, these findings paint a coherent picture of an industry at a pivotal inflection point — technically feasible in principle, yet not commercially viable at scale without targeted breakthroughs in production technology, institutional design, and political-economic strategy.

Production Costs and Reduction Potential

The evidence confirms that growth media — particularly the reliance on serum and costly recombinant growth factors — represents the single largest cost driver in cultured meat production [30, 43, 45]. Bioreactor operation and cell line development also contribute substantially [44, 46]. Crucially, these costs are not fixed: serum-free and growth factor-optimised media formulations [52, 62], alongside improved cell line efficiency, carry the greatest near-term reduction potential — with recombinant production of growth factors at scale offering a particularly high-leverage intervention [61, 34]. The pharmaceutical biomanufacturing record demonstrates that biological manufacturing can achieve order-of-magnitude cost reductions through the compounding interaction of learning curve effects, process intensification, and economies of scale, with monoclonal antibody production costs falling from thousands of dollars per gram to single-digit figures over approximately two decades [19, 20]. However, this trajectory was enabled by platform standardisation, pre-competitive knowledge sharing, and sustained capital investment that the cultured meat sector has not yet replicated. Cost parity with conventional meat will not emerge organically; it requires deliberate, coordinated investment in media cost reduction, process integration, and the accumulation of production experience sufficient to drive meaningful movement along the experience curve.

Technical Advances Driving Progress

Scaffolding, media engineering, and bioreactor design are advancing in parallel, and progress in each area is mutually reinforcing. Edible, biocompatible scaffolds now enable three-dimensional tissue formation at increasingly relevant scales [13, 14], providing the structural architecture necessary for cells to organize into fibrous, meat-like constructs. Serum-free media formulations are becoming more viable, reducing both cost and ethical concerns associated with conventional fetal bovine serum dependence [30, 52]. Bioreactor designs are evolving to support the oxygen transfer, shear stress tolerance, and nutrient delivery required for dense muscle tissue [46, 15]. No single technical advance is sufficient; commercial viability depends on achieving simultaneous maturity across all three domains. Evidence from pharmaceutical process intensification — where N-1 perfusion seeding strategies and integrated continuous manufacturing have demonstrated capital expenditure reductions of 20–76% and productivity improvements of three- to fivefold [33, 36, 20] — establishes credible precedent for the scale of cost improvement that bioreactor innovation could deliver, while simultaneously demonstrating that individual process levers must be co-optimised rather than pursued in isolation.

Regulatory Landscape

Regulatory frameworks vary substantially across jurisdictions, with the United States, European Union, Singapore, and Israel each adopting distinct approval pathways [11]. Singapore’s Food Agency made history in late 2020 by granting the world’s first market approval for a cultured chicken product, employing a three-step safety evaluation covering input materials, production controls, and compliance with food standards [11]. The United States operates a dual-agency framework dividing oversight between the FDA, which handles pre-market safety consultations, and the USDA-FSIS, which governs inspection and labelling; UPSIDE Foods completed this full review process by June 2023, becoming the first company to receive a USDA grant of inspection for cultivated chicken [11]. The EU, by contrast, applies its Novel Foods Regulation requiring lengthy EFSA scientific assessments, with no approvals yet granted, presenting a markedly more demanding pre-market approval structure [11]. Across all jurisdictions, safety substantiation, novel food classification, and labelling requirements form the common core of what approval demands [57]. Firms operating internationally must plan for multi-jurisdictional compliance from the outset, as regulatory divergence creates both market access barriers and strategic first-mover opportunities. Crucially, the political economy evidence demonstrates that regulatory divergence is not merely a product of different institutional traditions but is actively shaped by organised incumbent resistance — through lobbying, coalition-building, and labelling contestation — that constitutes a structural barrier to market access operating independently of technical readiness [25, 26].

Market Positioning and Consumer Acceptance

Consumer acceptance is heterogeneous and context-dependent, shaped by familiarity, cultural background, environmental values, and product framing [16, 18]. The “unnaturalness” perception remains the most persistent barrier [28], now understood through validated constructs such as food technology neophobia as a measurable psychological trait rather than a diffuse cultural sentiment [31, 16]. Established adoption frameworks — including Rogers’ Diffusion of Innovations and the Theory of Planned Behaviour — reveal that the observed heterogeneity reflects predictable patterns in innovation diffusion and that the attitude-behaviour gap among ethically motivated non-meat-eaters is structurally explicable rather than paradoxical [27, 17]. Pricing, transparency, and strategic product positioning — particularly in foodservice and premium segments as entry points — are the most actionable levers available to commercialising firms [89, 16]. Communication strategies that emphasise sustainability and food security benefits, without overclaiming, are likely to be most effective [17, 18], though information framing must be carefully calibrated to avoid the counterproductive effects of overly technical messaging [89].

Political Economy and the Institutional Dimensions of Viability

Economic viability is not purely a function of production cost reduction; it is co-determined by the political and institutional environment in which cultured meat must compete. Subsidy structures that artificially depress conventional meat prices, organised incumbent resistance through advocacy coalitions and regulatory capture, labelling disputes functioning as proxy battles over market legitimacy, and the geographic concentration of innovation in wealthy nations all shape the competitive landscape in ways that techno-economic models cannot capture. Empirical discourse network analysis of U.S. cellular agriculture policy coverage from 2008–2023 confirms the emergence of two sharply polarised coalitions — a pro-cellular agriculture bloc and a pro-animal agriculture bloc — with an E/I index of −0.88 indicating that congruence links occur overwhelmingly within rather than between coalitions, and with labelling disputes and product desirability constituting the primary axes of inter-coalition conflict [25]. The sociotechnical transitions literature establishes that cultured meat occupies a classic niche position facing a deeply entrenched regime whose destabilisation will require the simultaneous erosion of financial resources, external legitimacy, and internal cognitive commitment among incumbent actors — a process whose timeline is inherently political rather than technical [26, 39]. Justice and equity concerns — particularly the exclusion of Global South perspectives and livestock-dependent communities from governance of the transition — further condition the political legitimacy on which sustained public and regulatory support depends [41, 40].

Implications and Call to Action

Cultured meat has the scientific and commercial foundations to become a meaningful component of future food systems, but the path requires convergence across disciplines that rarely communicate at sufficient depth. Researchers, engineers, regulators, and commercial strategists must work in tighter coordination. Policymakers should prioritise creating clear, science-based regulatory pathways [11, 57] while addressing the subsidy asymmetries and labelling contestation that distort the competitive environment [25, 91]. Funders should target the cell culture media and scaffolding cost gaps specifically [43, 44], while also investing in the institutional infrastructure — pre-competitive data sharing consortia, open-source biological protocols, and inclusive governance mechanisms — that the innovation systems literature identifies as essential for cumulative industry-wide learning [38, 106]. The pharmaceutical biomanufacturing sector’s documented experience — in which sustained investment, platform standardisation, process intensification, and pre-competitive data sharing combined to drive transformative cost reduction over two decades [20, 36, 35] — provides an empirical roadmap whose deliberate adaptation to food-grade cellular agriculture could substantially accelerate the cultured meat industry’s economic trajectory. Equally, the sociotechnical transitions literature’s central insight — that system innovations require simultaneous transformation across technology, regulation, infrastructure, user practices, and cultural meanings [22, 21] — demands that the field treat political-institutional engagement not as a secondary concern but as a primary intervention point [39]. The window for establishing the evidence base that will underpin public trust and regulatory confidence is narrow, and it must be understood that this evidence base is not purely scientific but also political and institutional — the work must accelerate now on all fronts simultaneously.

---

References

[1] El Wali, M., Golroudbary, S., Krasławski, A., et al. (2024). Transition to cellular agriculture reduces agriculture land use and greenhouse gas emissions but increases demand for critical materials. Communications Earth & Environment. [2] Sinke, P., Swartz, E., Sanctorum, H., et al. (2023). Ex-ante life cycle assessment of commercial-scale cultivated meat production in 2030. The International Journal of Life Cycle Assessment. [3] Escobar, M., Cadena, E., Nhu, T., et al. (2021). Analysis of the Cultured Meat Production System in Function of Its Environmental Footprint: Current Status, Gaps and Recommendations. Foods. [4] Bhat, H., Fayaz, H. (2010). Prospectus of cultured meat—advancing meat alternatives. Journal of Food Science and Technology. [5] Letti, L., Karp, S., Molento, C., et al. (2021). Cultivated meat: recent technological developments, current market and future challenges. Biotechnology Research and Innovation. [6] Eibl, R., Senn, Y., Gubser, G., et al. (2021). Cellular Agriculture: Opportunities and Challenges. Annual Review of Food Science and Technology. [7] Stephens, N., Sexton, A., Driessen, C. (2019). Making Sense of Making Meat: Key Moments in the First 20 Years of Tissue Engineering Muscle to Make Food. Frontiers in Sustainable Food Systems. [8] Balasubramanian, B., Liu, W., Pushparaj, K., et al. (2021). The Epic of In Vitro Meat Production—A Fiction into Reality. Foods. [9] Lee, S., Lee, D., Yun, S., et al. (2023). Current technology and industrialization status of cell-cultivated meat. Journal of Animal Science and Technology. [10] Santos, A., Camarena, D., Reigado, G., et al. (2023). Tissue Engineering Challenges for Cultivated Meat to Meet the Real Demand of a Global Market. International Journal of Molecular Sciences. [11] Khan, I., Sun, J., Liang, W., et al. (2025). Innovations, Challenges, and Regulatory Pathways in Cultured Meat for a Sustainable Future. Foods. [12] Roy, N., Panda, S., Dey, G. (2023). Engineering a sustainable protein revolution: Recent advances in cultured meat production. Food Bioengineering. [13] Bomkamp, C., Skaalure, S., Fernando, G., et al. (2021). Scaffolding Biomaterials for 3D Cultivated Meat: Prospects and Challenges. Advanced Science. [14] Kawecki, N., Chen, K., Smith, C., et al. (2024). Scalable Processes for Culturing Meat Using Edible Scaffolds. Annual Review of Food Science and Technology. [15] Kulus, M., Jankowski, M., Kranc, W., et al. (2023). Bioreactors, scaffolds and microcarriers and in vitro meat production—current obstacles and potential solutions. Frontiers in Nutrition. [16] Bryant, C., Barnett, J. (2020). Consumer Acceptance of Cultured Meat: An Updated Review (2018–2020). Applied Sciences. [17] Lewisch, L., Riefler, P. (2023). Cultured meat acceptance for global food security: a systematic literature review and future research directions. Agricultural and Food Economics. [18] Szendrő, K. (2025). Consumer perceptions of lab-grown cells: Awareness, barriers, and the power of information. A review. Czech Journal of Animal Science. [19] Suzanne S. Farid (2006). Process economics of industrial monoclonal antibody manufacture. Journal of Chromatography B. [20] Niazi, S. (2025). Continuous Manufacturing of Recombinant Drugs: Comprehensive Analysis of Cost Reduction Strategies, Regulatory Pathways, and Global Implementation. Pharmaceuticals. [21] Frank W. Geels, Boelie Elzen, Ken Green (2004). General Introduction: System Innovation and Transitions to Sustainability. Edward Elgar Publishing eBooks. [22] Boelie Elzen, Frank W. Geels, Kenneth Green (2005). System Innovation and the Transition to Sustainability: Theory, Evidence and Policy. [23] Frank W. Geels (2010). Ontologies, socio-technical transitions (to sustainability), and the multi-level perspective. Research Policy. [24] El Bilali, H. (2019). The Multi-Level Perspective in Research on Sustainability Transitions in Agriculture and Food Systems: A Systematic Review. Agriculture. [25] Nadeau, N., Berardo, R. (2025). A new beef: An analysis of discourse coalitions in the nascent cellular agriculture policy subsystem. Review of Policy Research. [26] Turnheim, B., Geels, F. (2013). The destabilisation of existing regimes: Confronting a multi-dimensional framework with a case study of the British coal industry (1913–1967). Research Policy. [27] Dupont, J., Harms, T., Fiebelkorn, F. (2022). Acceptance of Cultured Meat in Germany—Application of an Extended Theory of Planned Behaviour. Foods. [28] Faccio, E., Fovino, L. (2019). Food Neophobia or Distrust of Novelties? Exploring Consumers’ Attitudes toward GMOs, Insects and Cultured Meat. Applied Sciences. [29] Özhava, D., Bhatia, M., Freman, J., et al. (2022). Sustainable Cell Sources for Cultivated Meat. Journal of Biomedical Research & Environmental Sciences. [30] Lee, D., Lee, S., Yun, S., et al. (2022). Review of the Current Research on Fetal Bovine Serum and the Development of Cultured Meat. Food Science of Animal Resources. [31] Lusk, J., Roosen, J., Bieberstein, A. (2014). Consumer Acceptance of New Food Technologies: Causes and Roots of Controversies. Annual Review of Resource Economics. [32] Pollock, J., Ho, S., Farid, S. (2012). Fed-Batch and Perfusion Culture Processes: Economic, Environmental, and Operational Feasibility Under Uncertainty. Biotechnology and Bioengineering. [33] Schaber, S., Gerogiorgis, D., Ramachnadran, R., et al. (2011). Economic Analysis of Integrated Continuous and Batch Pharmaceutical Manufacturing: A Case Study. Industrial & Engineering Chemistry Research. [34] Tripathi, N., Shrivastava, A. (2019). Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development. Frontiers in Bioengineering and Biotechnology. [35] Xu, W., Lin, Y., Mi, C., et al. (2023). Progress in fed-batch culture for recombinant protein production in CHO cells. Applied Microbiology and Biotechnology. [36] Xu, J., Rehmann, M., Xu, M., et al. (2020). Development of an intensified fed-batch production platform with doubled titers using N-1 perfusion seed for cell culture manufacturing. Bioresources and Bioprocessing. [37] Geels, F. (2011). The multi-level perspective on sustainability transitions: Responses to seven criticisms. Environmental Innovation and Societal Transitions. [38] Bergek, A., Hekkert, M., Jacobsson, S., et al. (2015). Technological innovation systems in contexts: Conceptualizing contextual structures and interaction dynamics. Environmental Innovation and Societal Transitions. [39] Mylan, J., Andrews, J., Maye, D. (2023). The big business of sustainable food production and consumption: Exploring the transition to alternative proteins. Proceedings of the National Academy of Sciences. [40] Chiles, R., Broad, G., Gagnon, M., et al. (2021). Democratizing ownership and participation in the 4th Industrial Revolution: challenges and opportunities in cellular agriculture. Agriculture and Human Values. [41] Moritz, J., Mazac, R., Ueta, M., et al. (2024). Prospects of Justice for Cellular Agriculture: A just Transition or Reinvesting in Unsustainability?. Food Ethics. [42] Bakhuis, J., Kamp, L., Barbour, N., et al. (2024). Frameworks for multi-system innovation analysis from a sociotechnical perspective: A systematic literature review. Technological Forecasting and Social Change. [43] Gu, H., Kong, Y., Huang, D., et al. (2025). Scaling Cultured Meat: Challenges and Solutions for Affordable Mass Production. Comprehensive Reviews in Food Science and Food Safety. [44] Negulescu, P., Risner, D., Spang, E., et al. (2023). Techno-economic modeling and assessment of cultivated meat: Impact of production bioreactor scale. Biotechnology and Bioengineering. [45] Humbird, D. (2021). Scale‐up economics for cultured meat. Biotechnology and Bioengineering. [46] Allan, S., De Bank, P., Ellis, M. (2019). Bioprocess Design Considerations for Cultured Meat Production With a Focus on the Expansion Bioreactor. Frontiers in Sustainable Food Systems. [47] Pajčin, I., Knežić, T., Azoulay, I., et al. (2022). Bioengineering Outlook on Cultivated Meat Production. Micromachines. [48] Singh, A., Kumar, V., Singh, S., et al. (2022). Recent advances in bioengineered scaffold for in vitro meat production. Cell and Tissue Research. [49] Reiss, J., Robertson, S., Suzuki, M. (2021). 410 — This article came from a journal that’s no longer in DOAJ. International Journal of Molecular Sciences. [50] Knežić, T., Janjušević, L., Djisalov, M., et al. (2022). Using Vertebrate Stem and Progenitor Cells for Cellular Agriculture, State-of-the-Art, Challenges, and Future Perspectives. Biomolecules. [51] Martins, B., Bister, A., Dohmen, R., et al. (2024). Advances and Challenges in Cell Biology for Cultured Meat. Annual Review of Animal Biosciences. [52] Stout, A., Mirliani, A., Rittenberg, M., et al. (2022). Simple and effective serum-free medium for sustained expansion of bovine satellite cells for cell cultured meat. Communications Biology. [53] Bomkamp, C., Musgrove, L., Marques, D., et al. (2022). Differentiation and Maturation of Muscle and Fat Cells in Cultivated Seafood: Lessons from Developmental Biology. Marine Biotechnology. [54] Kang, D., Choi, J., Park, Y., et al. (2025). Not just fish, but the future. Frontiers in Sustainable Food Systems. [55] Woelken, L., Weckowska, D., Dreher, C., et al. (2024). Toward an innovation radar for cultivated meat: exploring process technologies for cultivated meat and claims about their social impacts. Frontiers in Sustainable Food Systems. [56] Andrew J. Stout, Miles J. Arnett, Kristin M. Chai, et al. (2023). Immortalized Bovine Satellite Cells for Cultured Meat Applications. ACS Synthetic Biology. [57] Ong, K., Tejeda-Saldana, Y., Duffy, B., et al. (2023). Cultured Meat Safety Research Priorities: Regulatory and Governmental Perspectives. Foods. [58] Ong, K., Johnston, J., Datar, I., et al. (2021). Food safety considerations and research priorities for the cultured meat and seafood industry. Comprehensive Reviews in Food Science and Food Safety. [59] Skrivergaard, S., Young, J., Sahebekhtiari, N., et al. (2023). TR. Food Research International. [60] Andreassen, R., Pedersen, M., Kristoffersen, K., et al. (2020). Screening of by-products from the food industry as growth promoting agents in serum-free media for skeletal muscle cell culture. Food & Function. [61] Venkatesan, M., Semper, C., Skrivergaard, S., et al. (2022). Recombinant production of growth factors for application in cell culture. iScience. [62] Yamanaka, K., Haraguchi, Y., Takahashi, H., et al. (2023). Development of serum‑free and grain‑derived‑nutrient‑free medium using microalga‑derived nutrients and mammalian cell‑secreted growth factors for sustainable cultured meat production. Scientific Reports. [63] Barone, G., Emmerstorfer‐Augustin, A., Biundo, A., et al. (2023). Industrial Production of Proteins with Pichia pastoris—Komagataella phaffii. Biomolecules. [64] De Brabander, P., Uitterhaegen, E., Delmulle, T., et al. (2023). Challenges and progress towards industrial recombinant protein production in yeasts: A review. Biotechnology Advances. [65] Pakbin, B., Amanipour, A., Amirvaresi, A., et al. (2025). Development and optimization of an ammonia removal strategy for sustainable recycling of cell culture spent media in cultivated meat production: from concept to implementation. Frontiers in Bioengineering and Biotechnology. [66] Djisalov, M., Knežić, T., Podunavac, I., et al. (2021). Cultivating Multidisciplinarity: Manufacturing and Sensing Challenges in Cultured Meat Production. Biology. [67] Hatano, H., Sawada, M., Kitsukawa, M., et al. (2025). A Food-Grade Ready-to-Use Cell Culture Coating Agent Developed via Food Manufacturing: A Dual Technical and Regulatory Approach. [68] Bodiou, V., Moutsatsou, P., Post, M. (2020). Microcarriers for Upscaling Cultured Meat Production. Frontiers in Nutrition. [69] Perreault, L., Thyden, R., Kloster, J., et al. (2023). Repurposing agricultural waste as low-cost cultured meat scaffolds. Frontiers in Food Science and Technology. [70] Albrecht, F., Ahlfeld, T., Klatt, A., et al. (2024). Biofabrication’s Contribution to the Evolution of Cultured Meat. Advanced Healthcare Materials. [71] Bellani, C., Ajeian, J., Duffy, L., et al. (2020). Scale-Up Technologies for the Manufacture of Adherent Cells. Frontiers in Nutrition. [72] Hong, T., Shin, D., Choi, J., et al. (2021). Current Issues and Technical Advances in Cultured Meat Production: A Review. Food Science of Animal Resources. [73] Veena Warikoo, Rahul Godawat, Kevin Brower, et al. (2012). Integrated continuous production of recombinant therapeutic proteins. Biotechnology and Bioengineering. [74] Eslami, T., Jungbauer, A. (2024). Control strategy for biopharmaceutical production by model predictive control. Biotechnology Progress. [75] Välisalo, T., Salo, S., Wessberg, N., et al. (2025). Risk evaluation of a future B2B cell factory process producing cellular agriculture ingredients. Frontiers in Sustainable Food Systems. [76] Rubio, N., Xiang, N., Kaplan, D. (2020). Plant-based and cell-based approaches to meat production. Nature Communications. [77] Lee, H., Yong, H., Kim, M., et al. (2020). Status of meat alternatives and their potential role in the future meat market — A review. Asian-Australasian Journal of Animal Sciences. [78] Mark J. Post, Shulamit Levenberg, David L. Kaplan, et al. (2020). Scientific, sustainability and regulatory challenges of cultured meat. Nature Food. [79] Broucke, K., Van Pamel, E., Van Coillie, E., et al. (2023). Cultured meat and challenges ahead: A review on nutritional, technofunctional and sensorial properties, safety and legislation. Meat Science. [80] Renata Puppin Zandonadi, Maíra Catharina Ramos, Flávia Tavares Silva Elias, et al. (2025). Global Insights into Cultured Meat: Uncovering Production Processes, Potential Hazards, Regulatory Frameworks, and Key Challenges—A Scoping Review. Foods. [81] Hadi, J., Brightwell, G. (2021). Safety of Alternative Proteins: Technological, Environmental and Regulatory Aspects of Cultured Meat, Plant-Based Meat, Insect Protein and Single-Cell Protein. Foods. [82] Malila, Y., Owolabi, I., Chotanaphuti, T., et al. (2024). Current challenges of alternative proteins as future foods. npj Science of Food. [83] Gagnon, M., Broad, G., Grandison, K., et al. (2023). AgriTech investor and informant perspectives about cellular agriculture. The International Food and Agribusiness Management Review. [84] Stephens, N., Di Silvio, L., Dunsford, I., et al. (2018). Bringing cultured meat to market: Technical, socio-political, and regulatory challenges in cellular agriculture. Trends in Food Science & Technology. [85] Kavlak, G., McNerney, J., Trancik, J. (2018). Evaluating the causes of cost reduction in photovoltaic modules. Energy Policy. [86] Buarque, F., Lemes, A., Coelho, M. (2025). Advances in Industrial Biotechnology: Bioprocess and Bioseparation. Processes. [87] Yongli Ye, Jingwen Zhou, Xin Guan, et al. (2022). Commercialization of cultured meat products: Current status, challenges, and strategic prospects. Future Foods. [88] Zhu, H., Zhang, Z. (2025). Cultivated Meat: Pioneering Sustainable Solutions for Global Food Challenges. Food Chemistry International. [89] Lin‐Hi, N., Reimer, M., Schäfer, K., et al. (2022). Consumer acceptance of cultured meat: an empirical analysis of the role of organizational factors. Journal of Business Economics. [90] Tubb, C., Seba, T. (2020). Rethinking Food and Agriculture 2020-2030: The Second Domestication of Plants and Animals, the Disruption of the Cow, and the Collapse of Industrial Livestock Farming. [91] Treich, N. (2021). Cultured Meat: Promises and Challenges. Environmental and Resource Economics. [92] van Oorschot, J., Hofman, E., Halman, J. (2018). A bibliometric review of the innovation adoption literature. Technological Forecasting and Social Change. [93] Chang, M., Hsia, W., Chen, H. (2024). Breaking Conventional Eating Habits: Perception and Acceptance of 3D-Printed Food among Taiwanese University Students. Nutrients. [94] Горбунова, Н. (2025). ASSESSMENT OF THE CONSUMERS’ ATTITUDE TO THE ALTERNATIVE MEAT. REVIEW. Theory and practice of meat processing. [95] Victoria C. Krings, Kristof Dhont, Gordon Hodson (2021). Food technology neophobia as a psychological barrier to clean meat acceptance. Food Quality and Preference. [96] Zhang, N., Noor, S. (2026). The role of xiaohongshu in dietary acculturation and its influence on Chinese international students’ purchase intention for Malaysian traditional food. Decision Science Letters. [97] Karakuş, Y., Onat, G., Yılmaz, D. (2025). Modeling the Effect of Climate Change on Sustainable Food Consumption Behaviors: A Study on Artificial Meat and Edible Insects. Sustainability. [98] Mahya Tavan, Nick W. Smith, Warren C. McNabb, et al. (2025). Reassessing the sustainability promise of cultured meat: a critical review with new data perspectives. Critical Reviews in Food Science and Nutrition. [99] Zagury, Y., Ianovici, I., Landau, S., et al. (2022). Engineered marble-like bovine fat tissue for cultured meat. Communications Biology. [100] Peker, A., Orkan, Ş., Aral, Y., et al. (2024). A Comprehensive Outlook on Cultured Meat and Conventional Meat Production. Ankara Üniversitesi Veteriner Fakültesi Dergisi. [101] D’Almeida, A., de Albuquerque, T. (2025). Is It Possible to Produce Meat Without Animals? The Potential of Microorganisms as Protein Sources. Fermentation. [102] Kossmann, H., Moess, T., Breunig, P. (2025). The climate impact and land use of cultivated meat: Evaluating agricultural feedstock production. PLoS ONE. [103] Sau L. Lee, Thomas O’Connor, Xiaochuan Yang, et al. (2015). Modernizing Pharmaceutical Manufacturing: from Batch to Continuous Production. Journal of Pharmaceutical Innovation. [104] Jönsson, E. (2020). On breweries and bioreactors: Probing the “present futures” of cellular agriculture. Transactions of the Institute of British Geographers. [105] Andersson, J., Lennerfors, T., Fornstedt, H. (2023). Towards a socio-techno-ecological approach to sustainability transitions. Environmental Innovation and Societal Transitions. [106] Bergek, A., Jacobsson, S., Carlsson, B., et al. (2008). Analyzing the functional dynamics of technological innovation systems: A scheme of analysis. Research Policy.